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FOREWORD
 
The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public
 
Law 99-499) extended and amended the Comprehensive EnvironmentalResponse,
 
Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public
 
law directed the Agency for Toxic Substances and DiseaseRegistry (ATSDR) to
 
prepare toxicological profiles for hazardous substances which are most
 
commonly found at facilities on the CERCLA National Priorities List and which
 
pose the most significant potential threat to human health, as determined by
 
ATSDR and the Environmental Protection Agency (EPA). The lists of the 250
 
most significant hazardous substances were published in the Federal Register
 
on April 17, 1987, on October 20, 1988, on October 26, 1989, and on October
 
17, 1990.
 
Section 104(i)(3) of CERCLA, as amended, directs the Administrator of
 
ATSDR to prepare a toxicological profile for each substance on the list.
 
Each profile must include the following content:
 
(A) An examination, summary, and interpretation of available
 
toxicological information and epidemiological evaluations on the
 
hazardous substance in order to ascertain the levels of significant
 
human exposure for the substance and the associated acute, subacute,
 
and chronic health effects,
 
(B) A determination of whether adequate information on the health
 
effects of each substance is available or in the process of
 
development to determine levels of exposure which present a
 
significant risk to human health of acute, subacute, and chronic health
 
effects, and
 
(C) Where appropriate, an identification of toxicological testing
 
needed to identify the types or levels of exposure that may present
 
significant risk of adverse health effects in humans.
 
This toxicological profile is prepared in accordance with guidelines
 
developed by ATSDR and EPA. The original guidelines were published in the
 
Federal Register on April 17, 1987. Each profile will be revised and
 
republished as necessary, but no less often than every three years, as
 
required by CERCLA, as amended.
 
The ATSDR toxicological profile is intended to characterize succinctly
 
the toxicological and adverse health effects information for the hazardous
 
substance being described. Each profile identifies and reviews the key
 
literature (that has been peer-reviewed) that describes a hazardous
 
substance's toxicological properties. Other pertinent literature is also
 
presented but described in less detail than the key studies. The profile is
 
not intended to be an exhaustive document; however, more comprehensive
 
sources of specialty information are referenced.
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1. PUBLIC HEALTH STATEMENT
 
This Statement was prepared to give you information about ethylene
 
oxide and to emphasize the human health effects that may result from exposure
 
to it. The Environmental Protection Agency (EPA) has identified 1,177 sites
 
on its National Priorities List (NPL). Ethylene oxide has not been definitely
 
identified at any NPL site. However, it has been tentatively identified at
 
three of these sites. As EPA evaluates more sites, the number of sites at
 
which ethylene oxide is found may change. This information is important for
 
you to know because ethylene oxide may cause harmful health effects and
 
because these sites are potential or actual sources of human exposure to
 
ethylene oxide.
 
When a chemical is released from a large area, such as an
 
industrial plant, or from a container, such as a drum or bottle, it
 
enters the environment as a chemical emission. This emission, which is
 
also called a release, does not always lead to exposure. You can be
 
exposed to a chemical only when you come into contact with the chemical.
 
You may be exposed to it in the environment by breathing, eating, or
 
drinking substances containing the chemical or from skin contact with
 
it.
 
If you are exposed to a hazardous substance such as ethylene oxide,
 
several factors will determine whether harmful health effects will occur
 
and what the type and severity of those health effects will be. These
 
factors include the dose (how much), the duration (how long), the route
 
or pathway by which you are exposed (breathing, eating, drinking, or
 
skin contact), the other chemicals to which you are exposed, and your
 
individual characteristics such as age, sex, nutritional status, family
 
traits, life style, and state of health.
 
1.1 WHAT IS ETHYLENE OXIDE?
 
Ethylene oxide (also known as ET0 or oxirane) is a flammable gas
 
with a somewhat sweet odor. It dissolves easily in water, alcohol, and
 
most organic solvents.
 
Ethylene oxide is produced in large volumes and is used to make
 
other chemicals, especially ethylene glycol, a chemical used to make
 
antifreeze and polyester. Most ethylene oxide is used up in the
 
factories where it is produced. A very small amount (less than 1%) is
 
used to control insects on stored agricultural products such as nuts and
 
spices. Ethylene oxide is also used in very small amounts in hospitals
 
to sterilize medical equipment and supplies.
 
When ethylene oxide is produced or used, some of the gas is released
 
to air and water. If it is released into the air, humidity and sunlight
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cause it to break down within a few days. In water, ethylene oxide will
 
either break down or be destroyed by bacteria within a few days.
 
Further information on the properties and uses of ethylene oxide
 
can be found in Chapters 3, 4 and 5.
 
1.2 HOW MIGHT I BE EXPOSED TO ETHYLENE OXIDE?
 
You are not likely to be exposed to ethylene in the general
 
environment. In studies of the air quality in Texas and California, no
 
ethylene oxide was found. There is also no evidence that ethylene oxide
 
is commonly found in water. Because of the limited information about
 
ethylene oxide in air, water, or soil at hazardous waste sites, we do
 
not know how likely it is that you might be exposed to ethylene oxide at
 
or near these sites.
 
You may be exposed to ethylene oxide if you work where it is
 
produced or used. Health care workers, such as technicians, nurses, and
 
physicians in hospitals and clinics, may have contact with ethylene
 
oxide because it is used to sterilize medical equipment and supplies.
 
Since ethylene oxide is used as a fumigant to spray agricultural
 
products, if you are a farmer or work on a farm where ethylene oxide is
 
used, you may also be exposed to this substance.
 
It is not known if food crops are a source of exposure to ethylene
 
oxide for the general public. Ethylene oxide has been found at levels
 
up to 3.5 parts of ethylene oxide per one million parts of food
 
(3.5 ppm) in some foods shortly after being sprayed with pesticide that
 
contains it. These levels decrease with time as ethylene oxide
 
evaporates or breaks down into other substances, and thus little or none
 
may remain when the food is eaten.
 
Further information on the ways that you can be exposed to ethylene
 
oxide is presented in Chapter 5.
 
1.3 HOW CAN ETHYLENE OXIDE ENTER AND LEAVE MY BODY?
 
Ethylene oxide can enter your body when air containing this
 
substance is breathed into your lungs. Because ethylene oxide
 
evaporates very easily, it is unlikely that it remains in or on food or
 
remains dissolved in water long enough to be eaten or swallowed,
 
although this is not known for certain. It is not known if ethylene
 
oxide can enter the body through the skin.
 
After a person has been exposed to ethylene oxide, it leaves the
 
body through the urine or feces or by breathing it out through the
 
lungs. This probably occurs very rapidly, perhaps within 2 or 3 days.
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1.4 HOW CAN ETHYLENE OXIDE AFFECT MY HEALTH?
 
Ethylene oxide can cause a wide variety of harmful health effects
 
in exposed persons. In general, with higher levels of exposure to this
 
chemical, more severe effects will occur. The major effects seen in
 
workers exposed to ethylene oxide at low levels for several months or
 
years are irritation of the eyes, skin, and mucous membranes and
 
problems in the functioning of the brain and nerves. At higher levels
 
of exposure to ethylene oxide, which may result from accidents or
 
equipment breakdown, the types of effects are similar, but they are more
 
severe and harmful. There is also some evidence that exposure to
 
ethylene oxide can cause an increased rate of miscarriages in female
 
workers exposed to ethylene oxide.
 
Studies in animals have shown that breathing ethylene oxide at high
 
levels can interfere with their ability to reproduce. Litter sizes have
 
been smaller than usual, and the babies of exposed animals have weighed
 
less than normal and have had delayed bone formation.
 
Some studies of workers exposed to ethylene oxide in ethylene oxide
 
factories or hospital sterilizing rooms have shown an increased
 
incidence of leukemia, stomach cancer, cancer of the pancreas and
 
Hodgkin's disease. Ethylene oxide has also been shown to cause cancer
 
in laboratory animals. Leukemia, brain tumors, lung tumors and tumors
 
of the tear glands of the eye have been found.
 
Further information on the health effects of ethylene oxide is
 
presented in Chapter 2.
 
1.5 WHAT LEVELS OF EXPOSURE HAVE RESULTED IN HARMFUL HEALTH EFFECTS?
 
Tables 1-1 through 1-4 show the relationship between exposure to
 
ethylene oxide and known health effects. Skin contact with ethylene
 
oxide can result in blisters and burns that may appear to be similar to
 
frostbite. With longer times of contact, there is a more severe
 
reaction. Eye damage can also result from ethylene oxide contact.
 
It is possible to smell ethylene oxide if it is present in water at
 
or above 140 mg per liter (about one quart) of water. It can also be
 
smelled in air if it is present at or above 430 ppm (430 parts of
 
ethylene oxide per million parts of air).
 
A Minimal Risk Level (MRL) is also included in Table l-l. This MRL
 
was derived from animal data for long-term exposure, as described in
 
Chapter 2 and in Table 2-l. The MRL provides a basis for comparison
 
with levels that people might encounter in the air. If a person is
 
exposed to ethylene oxide at an amount below the MRL, it is not expected
 
that harmful (noncancer) health effects will occur. Because this level
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is based only on information currently available, some uncertainty is
 
always associated with it. Also, because the method for deriving MRLs
 
does not use any information about cancer, an MRL does not imply
 
anything about the presence, absence, or level of risk for cancer.
 
Further information on exposure levels of ethylene oxide that cause
 
health effects in humans and animals is presented in Chapter 2.
 
1.6	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
 
ETHYLENE OXIDE?
 
There are two kinds of tests that can determine if you have been
 
exposed to ethylene oxide within the last couple of days. These tests
 
are not routinely done in a doctor's office, but can be done in a
 
special laboratory. One test measures this substance in blood, the
 
other measures it in air that you breathe out of your lungs. If you
 
were exposed to ethylene oxide more than two or three days ago, there
 
may be no ethylene oxide remaining in your body. In addition, if you
 
have been exposed to very low levels of ethylene oxide, these tests may
 
not detect it. The results of these tests cannot be used to predict the
 
type or severity of health effects resulting from exposure.
 
Further information on this topic is presented in Chapter 2 and 6.
 
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN
 
HEALTH?
 
In order to protect the general population from exposure to
 
ethylene oxide, the federal government has established a number of
 
guidelines and regulations related to its use and disposal.
 
The EPA is considering listing ethylene oxide as a hazardous air
 
pollutant and regulating industrial emissions. The Food and Drug
 
Administration (FDA) has set limits on the levels of ethylene oxide that
 
may remain on food products fumigated with this chemical. In order to
 
protect workers who use ethylene oxide while on the job, the
 
Occupational Safety and Health Administration (OSHA) has established a
 
limit of 1 ppm in workplace air for an 8-hour work day and a limit of
 
5 ppm for a 15-minute period.
 
More detailed information on federal and state regulations
 
regarding ethylene oxide is given in Chapter 7.
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1.8 WHERE CAN I GET MORE INFORMATION?
 
If you have any more questions or concerns not covered here, please
 
contact your State Health or Environmental Department or:
 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology
 
1600 Clifton Road, E-29
 
Atlanta, Georgia 30333
 
This agency can also give you information on the location of the
 
nearest occupational and environmental health clinics. Such clinics
 
specialize in recognizing, evaluating, and treating illnesses that
 
result from exposure to hazardous substances.
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2.1 INTRODUCTION
 
This chapter contains descriptions and evaluations of studies and
 
interpretation of data on the health effects associated with exposure to
 
ethylene oxide. Its purpose is to present levels of significant
 
exposure for ethylene oxide based on toxicological studies,
 
epidemiological investigations and environmental exposure data. This
 
information is presented to provide public health officials, physicians,
 
toxicologists and other interested individuals and groups with (1) an
 
overall perspective of the toxicology of ethylene oxide and (2) a
 
depiction of significant exposure levels associated with various adverse
 
health effects.
 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
 
To help public health professionals address the needs of persons
 
living or working near hazardous waste sites, the data in this section
 
are organized first by route of exposure -- inhalation, oral and dermal
 
-- and then by health effect -- death, systemic, immunological,
 
neurological, developmental, reproductive, genotoxic and carcinogenic
 
effects. These data are discussed in terms of three exposure periods -­
acute, intermediate and chronic.
 
Levels of significant exposure for each exposure route and duration
 
(for which data exist) are presented in tables and illustrated in
 
figures. The points in the figures showing no-observed-adverse-effect
 
levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs)
 
reflect the actual doses (levels of exposure) used in the studies.
 
LOAELs have been classified into "less serious" or "serious" effects.
 
These distinctions are intended to help the users of the document
 
identify the levels of exposure at which adverse health effects start to
 
appear, determine whether or not the intensity of the effects varies
 
with dose and/or duration and place into perspective the possible
 
significance of these effects to human health.
 
The significance of the exposure levels shown on the tables and
 
figures may differ depending on the user's perspective. For example,
 
physicians concerned with the interpretation of clinical findings in
 
exposed persons or with the identification of persons with the potential
 
to develop such disease may be interested in levels of exposure
 
associated with "serious" effects. Public health officials and project
 
managers concerned with response actions at Superfund sites may want
 
information on levels of exposure associated with more subtle effects in
 
humans or animals (LOAELs) or exposure levels below which no adverse
 
effects (NOAELs) have been observed. Estimates of levels posing minimal
 
risk to humans (Minimal Risk Levels, MRLs) are of interest to health
 
professionals and citizens alike.
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For certain chemicals, levels of exposure associated with
 
carcinogenic effects may be indicated in the figures. These levels
 
reflect the actual doses associated with the tumor incidences reported
 
in the studies cited. Because cancer effects could occur at lower
 
exposure levels, the figures also show estimated excess risks, ranging
 
from a risk of one in 10,000 to one in 10,000,000 (10-4 to l0-7), as
 
developed by EPA.
 
Estimates of exposure levels posing minimal risk to humans (MRLs)
 
have been made, where data were believed reliable, for the most
 
sensitive noncancer end point for each exposure duration. MRLs include
 
adjustments to reflect human variability and, where appropriate, the
 
uncertainty of extrapolating from laboratory animal data to humans.
 
Although methods have been established to derive these levels (Barnes
 
et al. 1987; EPA 1989), uncertainties are associated with the
 
techniques.
 
2.2.1 Inhalation Exposure
 
Most information on the health effects of ethylene oxide is derived
 
from animal inhalation studies or epidemiological or case studies of
 
persons in occupational settings. The most relevant route of exposure
 
to a volatile compound such as ethylene oxide in an occupational setting
 
is via inhalation. It is important to note, however, that there may be
 
dermal exposure, either directly or through the air, and any food on the
 
premises may similarly be contaminated, resulting in possible oral
 
exposure.
 
2.2.1.1 Death
 
The available studies on humans exposed to ethylene oxide in the
 
workplace indicate that there is no increase in mortality associated
 
with those exposures (Gardner et al. 1989; Greenberg et al. 1990;
 
Kiesselbach et al. 1990).
 
Estimates of lethal ethylene oxide inhalation levels in animals
 
depend on the exposure duration. In mice, exposures to 800 ppm for four
 
hours resulted in 80-100% mortality, whereas 400 ppm exposures for
 
14 days did not result in death (NTP 1987). Jacobson et al. (1956)
 
reported that the 4-hour LC50 values for rats, mice and dogs were 1,460,
 
835 and 960 ppm, respectively.
 
In two-year studies using mice (NTP 1987) and monkeys (Lynch et al.
 
1984a), exposure to 100 ppm did not result in increased mortality in the
 
test animals.
 
The highest NOAEL values and all reliable LOAEL values for death in
 
each species are presented in Table 2-l and plotted in Figure 2-1.
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2.2.1.2 Systemic Effects
 
Respiratory Effects. Inhalation of ethylene oxide is irritating to
 
mucous membranes including those associated with the respiratory system.
 
Inhalation exposure of workers to high concentrations of ethylene oxide
 
for brief periods has resulted in bronchitis, pulmonary edema, and
 
emphysema (Theiss 1963). Studies on long-term human exposure to
 
ethylene oxide do not address the incidence of respiratory problems.
 
Respiratory irritation has been reported in animal studies at
 
various exposure levels. In lethality studies, mice exposed to 200 ppm
 
and above for 14 weeks exhibited nasal irritation, necrosis of
 
epithelium, and loss of cilia (NTP 1987). These lesions were not seen
 
in mice exposed to 100 ppm for two years (NTP 1987).
 
The highest NOAEL values and all reliable LOAEL values for
 
respiratory effects in each species and duration category are presented
 
in Table 2-l and plotted in Figure 2-l.
 
Cardiovascular Effects. Studies of humans and animals exposed to
 
ethylene oxide via inhalation have not reported evidence of injury to
 
the cardiovascular system. In a study of male monkeys exposed to
 
ethylene oxide at levels up to 100 ppm for two years, no treatment related
 
changes were observed in routine electrocardiograms taken
 
throughout the study (Lynch et al. 1984a).
 
Gastrointestinal Effects. Studies of humans and animals exposed to
 
ethylene oxide via inhalation have not addressed the potential
 
gastrointestinal effects of these exposures. Nausea and vomiting have
 
been reported, but these are considered to be secondary effects due to
 
neurotoxicity rather than a primary effect of inhaled ethylene oxide on
 
the gastrointestinal tract. (See Section 2.2.1.4)
 
Hematological Effects. Most studies of human exposure to ethylene
 
oxide via inhalation have not examined the potential adverse
 
hematological effects of this compound. Joyner (1964) reported no
 
effects on hemoglobin levels or red or white blood cell counts in
 
workers exposed to ethylene oxide at about 5-10 ppm for approximately
 
10 years. Data reported in case studies of individuals exposed to
 
ethylene oxide in occupational settings do not provide quantifiable
 
information due to the small numbers of subjects and lack of information
 
on the level of ethylene oxide exposure.
 
A 10-week exposure of mice to ethylene oxide at 250 ppm resulted in
 
slight but statistically significant decreases in red blood cell numbers
 
and blood hemoglobin concentrations. These effects were not seen at
 
100 ppm or below (Snellings et al. 1984a). Two-year studies of rats,
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monkey (Lynch et al. 1984a) and mice (NTP 1987) have reported that
 
chronic exposure to 100 ppm did not have any observable hematological
 
effects.
 
Thus, it is not clear if hematological effects are an area of
 
Concern associated with inhalation exposure to ethylene oxide.
 
Musculoskeletal Effects.  No studies were located regarding
 
Musculoskeletal effects in humans after inhalation exposure to ethylene
 
oxide.
 
Lynch et al. (1984b) reported an increased incidence of skeletal
 
Muscle myopathy in rats exposed to ethylene oxide at 100 ppm by
 
Inhalation. Lesions consisted of multifocal areas of atrophy and
 
Degeneration of skeletal muscle fibers.
 
Hepatic Effects.  Information regarding hepatic effects in humane
 
After inhalation exposure to ethylene oxide is limited to a report by
 
Joyner (1964) which indicated that workers exposed to about 5-10 ppm for
 
10 years did not have major signs of hepatic toxicity such as jaundice
 
or palpable liver.
 
The data on hepatic effects in animal studies are sparse.
 
Qualitative evidence of liver damage is available in an earlier acute-

duration study by Hollingsworth et al. (1956) Rats and guinea pigs
 
given two and three sever-hour exposures, respectively, to ethylene
 
oxide at 841 ppm were reported to have light coloration and fatty
 
degeneration of the liver. Because the authors did not specify which
 
species was observed to have the stated lesions, or what observations
 
were made in control animals, the reported results are difficult to
 
Interpret.
 
Adverse hepatic effects have not been reported in the more recent
 
literature, most notably in the NTP (1987) 14-week study in which mice were
 
exposed to ethylene oxide at doses up to 600 ppm. Snellings et al. (1984a)
 
reported an elevation in the liver to body weight ratio in female mice
 
exposed to ethylene oxide at 250 ppm for 11 weeks; however, histological
 
examination showed that the livers were normal at this and all other lower
 
exposure levels for both sexes in this study. No hepatic effects have been
 
reported in chronic studies.
 
The highest NOAEL value and all reliable LOAEL values for each
 
Species and duration category are presented in Table 2-1 and plotted in
 
Figure 2-1.
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Renal Effects. Information regarding renal effects in humans after
 
inhalation exposure to ethylene oxide is limited to a report by Joyner
 
(1964) which indicates that there was no evidence of nephritis or other
 
parenchymal disease among workers exposed to ethylene oxide at 5-10 ppm
 
for 10 years.
 
In animal studies, qualitative evidence of renal effects resulting
 
from acute exposure was presented in an earlier study, Hollingsworth
 
et al. (1956), in which rats and guinea pigs were given two and three
 
seven-hour exposures, respectively, to ethylene oxide at 841 ppm. Renal
 
enlargement and slight congestion and cloudy swelling of the convoluted
 
tubules were reported. As described previously, there are certain
 
limitations in this study (i.e., the results observed in controls were
 
not indicated and the authors did not indicate the species in which each
 
lesion was observed).
 
Renal lesions have also been reported in a 14-week study in mice by
 
NTP (1987). Exposure to 100 ppm resulted in tubular degeneration in
 
male mice and to 600 ppm in tubular necrosis in both sexes. No renal
 
lesions were observed in mice exposed to ethylene oxide at 50 ppm. This
 
value has been used to calculate the minimum risk level (MRL) for
 
intermediate inhalation exposure as shown in Figure 2-l. Renal lesions
 
seen at 100 ppm in the 14-week study, however, were not observed at that
 
level (the highest tested) in the two-year study in mice by NTP (1987).
 
The authors attributed this disparity to the confounding influence of
 
subtle age-related lesions in the kidneys of mice in the two-year study.
 
Therefore, renal effects appear to be an area of some concern for
 
inhalation exposure to ethylene oxide. The highest NOAEL values and all
 
reliable LOAEL values for renal effects in each species and duration
 
category are presented in Table 2-l and plotted in Figure 2-1.
 
Dermal/Ocular Effects. There is some evidence that occupational
 
exposure to high levels of ethylene oxide can result in cataracts. This
 
is based on the cases of four sterilizer operators who were exposed to
 
ethylene oxide from a leaking sterilizer for up to two months (Gross
 
et al. 1979). In the next 2.5 to 3.5 years, Jay et al. (1982) found
 
that all four men had developed cataracts. Because these persons could
 
intermittently smell the fumes, a level of 700 ppm or more was estimated
 
by the authors in retrospect. Although none of the patients were
 
examined before this accidental exposure, the occurrence of cataracts
 
was viewed as unlikely to be a chance occurrence in all four persons in
 
this age range (31 to 35 years old) who had no systemic or ocular
 
disease that might be associated with cataract formation.
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Lynch et al. (1984a) observed a dose-related but not statistically
 
significant increase in the incidence of cataracts in rats exposed to
 
ethylene oxide at 50 and 100 ppm for two years. Therefore, the
 
potential for adverse ocular effects may be an area of concern in cases
 
of chronic or high level inhalation exposure to ethylene oxide. The
 
available data, however, are not useful to serve as the basis for
 
quantifying effect levels for cataract formation in humans.
 
Other Effects. Proliferative and degenerative lesions of the
 
adrenal cortex, consisting of vacuolation and hyperplasia or hypertrophy
 
of the zona fascicularis, have been reported in rats exposed to ethylene
 
oxide at 50 or 100 ppm in a 2-year study by Lynch et al. (1984b). Focal
 
to multifocal splenic fibrosis and extramedullary hematopoiesis were
 
also reported in these rats.
 
2.2.1.3 Immunological Effects
 
The immunological effects of human inhalation exposure to ethylene
 
oxide were studied in workers in an ethylene oxide manufacturing plant
 
for up to 14 years. Atmospheric concentrations were generally below
 
0.05 ppm (the detection limit of the analytical method) with occasional
 
peaks of 8 ppm during the 4 years that the air was monitored. There was
 
no effect on any of the blood parameters relating to immune function
 
that were investigated, including T and B lymphocyte counts, lymphocyte
 
activation, and serum IgG, IgM, and IgA levels (Van Sittert et al.
 
1985). Theiss (1963) did not observe skin sensitization in ethylene
 
oxide plant workers (average exposure: 10.4 years) who were challenged
 
with a single dermal application of 1% ethylene oxide.
 
In mice exposed to ethylene oxide during a 14-week study,
 
lymphocytic hypoplasia of the thymus was seen in males in the 200 ppm
 
exposure group. At 600 ppm, lymphocytic necrosis of the thymus was seen
 
in most mice of both sexes, and lymphocytic necrosis of the spleen was
 
seen in males.
 
2.2.1.4 Neurological Effects
 
Neurological effects have frequently been reported in association
 
with human and animal exposure to ethylene oxide via inhalation at a
 
wide range of concentrations and exposure durations.
 
In humans exposed to high levels of ethylene oxide in occupational
 
settings, headache, nausea and vomiting have been reported for decades
 
(Blackwood and Erskine 1938; von Oettingen 1939; Sexton and Henson
 
1949). Exposure levels were not measured or estimated in these
 
situations.
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Peripheral neuropathy, impaired hand-eye coordination, and memory
 
loss have also been reported in more recent case studies of workers
 
exposed to ethylene oxide for various durations (Crystal et al. 1988;
 
Estrin et al. 1987; Finelli et al. 1983; Kuzuhara et al. 1983; Salinas
 
et al. 1981; Schroeder et al. 1985; Zampollo et al. 1984). These
 
effects were seen at estimated average exposure levels as low as 3 ppm;
 
however, short-term exposures may have been as high as 700 ppm for some
 
of these workers. Two of these studies indicated that sural nerve
 
biopsies showed axonal degeneration and regeneration (Kuzuhara et al.
 
1983; Schroeder et al. 1985).
 
Information on the neurological effects of inhalation exposure to
 
ethylene oxide has also been derived from case studies of longer-term
 
occupational exposure. Four sterilizer operators exposed to ethylene
 
oxide for up to two months on an intermittent basis at levels of
 
approximately 700 ppm (estimated by the authors based on the fact that
 
the exposed workers could smell the vapors emitted from a leaking
 
apparatus) reported headaches, nausea, vomiting, clumsiness, blunting of
 
the senses, lethargy, numbness and weakness in the extremities, and, in
 
the case of one operator, recurrent major motor seizures at 20- to
 
30-minute intervals near the end of the work shift. Nerve conduction
 
studies indicated sensimotor neuropathy. These conditions were reversed
 
in the case of one of these operators who was returned to a position
 
without ethylene oxide exposure, but the results of nerve conduction
 
studies remained abnormal in the cases of two of the three workers who
 
were returned to positions of lower ethylene oxide exposure (50 ppm or
 
less) (Gross et al. 1979). However, the possibility of occasional
 
short-term exposure to high levels of ethylene oxide after that point
 
was not addressed.
 
In subchronic studies in mice, exposure to ethylene oxide at 50 ppm
 
and above for l0-11 weeks resulted in hunched posture, reduced locomotor
 
activity and abnormal righting reflexes (Snellings et al. 1984a).
 
In earlier animal studies, exposures of various species to
 
moderately high levels of ethylene oxide (357 ppm) for up to 6 months
 
resulted in neurological impairment, including reversible hind leg
 
paralysis and atrophy, abnormal knee and extensor reflexes and
 
diminished pain perception (Hollingsworth et al. 1956). The exposure of
 
monkeys to 200 ppm for about 7 months in another phase of this study
 
resulted in partial paralysis, muscular atrophy of the hind legs and
 
suppression of reflexes. Due to inconsistencies in the testing protocol
 
and reporting of results, the Hollingsworth et al. (1956) study can be
 
viewed only as qualitative evidence of a broad range of neurological
 
effects associated with inhalation of ethylene oxide at these levels.
 
In a 9-month study of rats exposed to ethylene oxide at 250 ppm,
 
distal axonal degeneration of myelinated fibers in both sural nerves and
 
gracile fascicles was reported (Ohnishi et al. 1986). Observations of
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neurological effects in two-year studies have ranged from no effects
 
observed in mice exposed to 100 ppm (NTP 1987) to slight demyelination
 
of the brain of monkeys exposed at the same level (Lynch et al. 1984a)
 
and brain lesions seen in rats exposed at 50 ppm (Lynch et al. 1984a,
 
1984b).
 
The highest NOAEL values and all reliable LOAEL values for
 
neurotoxicity in each species and duration category are presented in
 
Table 2-l and plotted in Figure 2-l.
 
2.2.1.5 Developmental Effects
 
No studies were located regarding developmental effects in humans
 
after inhalation exposure to ethylene oxide.
 
Data available from animal studies indicate that ethylene oxide was
 
not teratogenic in rats exposed at 100 ppm during gestation (Snellings
 
et al. 1982a) or in rats or rabbits at an exposure level of 150 ppm
 
during gestation (Hardin et al. 1983).
 
Embryo and fetal toxicities, however, were evident in rats exposed
 
to 100 ppm in the Snellings et al. (1982a) study, as indicated by an
 
increased incidence of resorption and reductions in fetal body weight
 
and crown-rump length and reduced skeletal ossification of the skull and
 
sternebrae. The highest NOAEL values and all reliable LOAEL values for
 
developmental toxicity in each species and duration category are
 
presented in Table 2-l and plotted in Figure 2-l.
 
2.2.1.6 Reproductive Effects
 
There is limited evidence in both animal and human studies that
 
inhalation exposure to ethylene oxide can result in adverse reproductive
 
effects, although there is currently no clear pattern in the nature of
 
those effects.
 
Data in humans are limited. In an epidemiological study by
 
Hemminki et al. (1982), the spontaneous abortion rates in ethylene oxide
 
sterilizer personnel in hospitals in Finland were found to be
 
significantly higher than those of non-exposed workers. Although
 
exposure levels were not measured, the authors estimated that 8-hour
 
weighted mean concentrations ranging from 0.1 to 0.5 ppm with peaks to
 
250 ppm were associated with adverse outcomes. Various limitations have
 
been described in the design and implementation of this study including
 
recall bias, prior knowledge of the questionnaires and analysis based on
 
too few pregnancies (Golberg 1986). Decreased sperm counts in ethylene
 
oxide workers were reported by Abrahams (1980). However, based on the
 
small number of sperm samples obtained, the author viewed the results as
 
inconclusive.
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Various adverse reproductive effects have also been noted in animal
 
studies, including a decreased number of implantation sites in rats
 
exposed to ethylene oxide at 100 ppm during gestation (Snellings et al.
 
1982b), decreased testicular weights in mice exposed to 50 ppm or more
 
for 10 weeks (Snellings et al. 1984a), decreased testicular weights and
 
testicular degeneration in guinea pigs exposed to 375 ppm for about
 
6 months, and testicular degeneration in rats exposed to 204 ppm for
 
about 6 months (Hollingsworth et al. 1956). In Cynomolgus monkeys
 
exposed to ethylene oxide at 50 or 100 ppm for two years, sperm
 
concentration, motility and drive range, as well as decreased testicular
 
and epididymal weights, were observed (Lynch et al. 1984a). Appelgren
 
et al. (1977) demonstrated that in mice intravenously injected with
 
14C-ethylene oxide, the 14C-label was detected in the testes and
 
epididymis (at undetermined levels) within four hours. This study
 
indicates that ethylene oxide or one of its degradation products can be
 
distributed to the male reproductive system.
 
Therefore, it appears that both female and male reproductive
 
systems are potential targets of ethylene oxide toxicity.
 
The highest NOAEL values and all reliable LOAEL values for
 
reproductive toxicity in each species and duration category are
 
presented in Table 2-1 and plotted in Figure 2-1.
 
2.2.1.7 Genotoxic Effects
 
In studies of workers exposed to ethylene oxide, analysis of
 
peripheral blood lymphocytes resulted in the detection of various
 
chromosomal aberrations including breaks, gaps, and exchanges and
 
supernumerary chromosomes (Pero et al. 1981; Galloway et al. 1986; Sarto
 
et al. 1984a; Theiss et al. 1981). An increased incidence of sister
 
chromatid exchange (SCE) in the peripheral lymphocytes of ethylene oxide
 
workers has also been reported by Galloway et al. (1986), Garry et al.
 
(1979), Lambert and Lindblad (1980), Sarto et al. (1984a, 1984b),
 
Stolley et al. (1984), and Yager et al, (1983).
 
Inhalation studies with rats indicate that ethylene oxide at 50 ppm
 
or more for 3 days resulted in an increase in SCE (Kligerman et al.
 
1983). Increased incidences of SCE and chromosomal aberrations in the
 
peripheral blood of monkeys exposed to ethylene oxide at 500 or 100 ppm
 
were reported by Lynch et al. (1984a). A follow-up study in these same
 
monkeys by Kelsey et al. (1988) indicated that high SCE counts persisted
 
6 years after exposure.
 
In dominant lethal assays, ethylene oxide administered via
 
inhalation has resulted in a positive response in mice (Cumming and
 
Michaud 1979; Generoso et al. 1986, 1988) and rats (Embree et al. 1977).
 
Dose-rate studies by Generoso et al. (1986) have demonstrated that short
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bursts of ethylene oxide at high concentrations, such as those that may
 
occur in the workplace, may present a greater risk to germ cell damage
 
than does cumulative, long-term exposure to lower levels. Data from
 
these studies are viewed as providing support to the concern for the
 
potential genotoxicity of this compound.
 
2.2.1.8 Cancer
 
There is some evidence from inhalation data in both humans and
 
animals that ethylene oxide is carcinogenic by this route. However, the
 
available data in humans are considered to be limited and inconclusive.
 
Epidemiological studies of workers exposed to ethylene oxide in hospital
 
sterilizing operations and in manufacturing plants (Hogstedt et al.
 
1979, 1986) have reported increased incidences of leukemia and stomach
 
cancer. The Hogstedt data are viewed as having certain limitations,
 
however, such as the small cohort size, the small number of deaths that
 
occurred, and uncertainties about the exposure levels (Golberg 1986).
 
Data (originally reported as negative) by Morgan et al. (1981), when
 
reanalyzed by EPA (1985a), showed an increased rate of mortality from
 
pancreatic cancer and Hodgkin's disease in ethylene oxide-exposed
 
workers. No clear excess in any of these cancers, however, was found by
 
Gardner et al. (1989), Greenberg et al. (1990) or Kiesselbach et al.
 
(1990).
 
In two-year studies of rats exposed to ethylene oxide at 33 to
 
100 ppm and 50 to 100 ppm, increased incidences of mononuclear cell
 
leukemia, peritoneal mesotheliomas, and various brain tumors have been
 
reported at all dose levels tested (Lynch et al. 1984b; Snellings et al.
 
1984b). The finding of mononuclear cell leukemia in rats may be of
 
dubious significance to humans because this is a spontaneous tumor in
 
Fischer-344 rats and because the human equivalent of this disease is
 
T-gamma lymphoproliferative disease (lymphocytosis), not leukemia.
 
In an NTP (1987) two-year inhalation study of mice at 50 and
 
100 ppm, alveolar/bronchiolar carcinomas and adenomas, papillary
 
cystadenomas of the harderian gland, malignant lymphomas, uterine
 
adenocarcinomas, and mammary gland tumors were increased in one or more
 
exposure groups. The cancer effect levels (CEL'S) are presented in
 
Table 2-l and plotted in Figure 2-l.
 
On the basis of the combined incidence of mononuclear cell leukemia
 
and gliomas in female rats in the Snellings et al. (1984b) inhalation
 
study, an upper-limit carcinogenicity potency value for ethylene oxide
 
has been calculated as 3.5 x 10-l (mg/kg/day)-l by EPA (1985a) using the
 
linearized multistage model.
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EPA's Cancer Assessment Group has found the evidence in animal
 
studies to be "sufficient" and the human evidence to be "limited"
 
bordering on inadequate to establish ethylene oxide as a probable human
 
carcinogen (EPA 1985a). This results in a Group Bl bordering on B2
 
carcinogenicity classification for this compound. Similarly, according
 
to IARC guidelines, ethylene oxide has been classified in Group 2A
 
bordering on 2B due to the limitations in human evidence (IARC 1987).
 
2.2.2 Oral Exposure
 
Data on the toxic effects following oral administration of ethylene
 
oxide are extremely limited and no studies are considered appropriate
 
for the calculation of Minimal Risk Levels. As mentioned previously,
 
inhalation is considered to be the most important route of exposure for
 
this chemical.
 
2.2.2.1 Death
 
No information was located on the lethal effects in humans after
 
oral exposure to ethylene oxide.
 
In a study using rats, Hollingsworth et al. (1956) found that a
 
single gavage dose of ethylene oxide at 200 mg/kg resulted in the death
 
of all test animals. At 100 mg/kg, all animals survived 15 doses
 
administered in 21 days. Based on these results, the oral LD50 would
 
probably be somewhere between these two dosage levels. It should be
 
noted that this study used a small number of test animals (5/dose) and
 
the results should be viewed in consideration of this study limitation.
 
These values are presented in Table 2-2 and plotted in Figure 2-2.
 
2.2.2.2 Systemic Effects
 
No studies were located on the respiratory, cardiovascular,
 
musculoskeletal, renal or dermal effects in humans or animals after oral
 
exposure to ethylene oxide.
 
Gastrointestinal Effects. No studies were located on the
 
gastrointestinal effects in humans after oral exposure to ethylene
 
oxide.
 
Hollingsworth et al. (1956) reported gastric irritation in female
 
rats receiving 15 doses of ethylene oxide by gavage at 100 mg/kg/day for
 
21 days. This effect was not observed at doses of 30 mg/kg/day or below
 
in rats dosed 22 times in 30 days. Due to the small number of test
 
animals used (5/dose) and the lack of detail in reporting results,
 
especially in control animals, the value of this study is limited.
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These values have been presented in Table 2-2 and plotted in
 
Figure 2-2.
 
Hematological Effects. No studies were located regarding the
 
hematological effects in humans after oral exposure to ethylene oxide.
 
Hollingsworth et al. (1956) reported that there were no adverse
 
hematological effects in female rats receiving ethylene oxide by gavage
 
at levels up to 100 mg/kg/day at 15 doses in 21 days. No other details
 
were provided.
 
Based on the limitations of the available data, it is not clear if
 
hematological effects would be an area of potential concern for oral
 
exposure to ethylene oxide.
 
Hepatic Effects. No studies were located regarding hepatic effects
 
in humans after oral exposure to ethylene oxide.
 
Slight liver damage (no further details) was reported by
 
Hollingsworth et al. (1956) in rats exposed by gavage to ethylene oxide
 
at 100 mg/kg/day for 15 doses in 21 days, but not in animals receiving
 
up to 30 mg/kg/day for 22 doses in 30 days. Because of various
 
limitations in the scope and reporting of this study, it can be viewed
 
only as suggestive evidence that oral exposure to ethylene oxide can
 
result in hepatic effects.
 
These values have been presented in Table 2-2 and plotted in
 
Figure 2-2.
 
No studies were located regarding the following health effects in
 
humans or animals after oral exposure to ethylene oxide:
 
2.2.2.3 Immunological Effects
 
2.2.2.4 Neurological Effects
 
2.2.2.5 Developmental Effects
 
2.2.2.6 Reproductive Effects
 
2.2.2.7 Genotoxic Effects
 
2.2.2.8 Cancer
 
No studies were located regarding carcinogenic effects in humans
 
after oral exposure to ethylene oxide.
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In the only animal study available via this route, Dunkelberg
 
(1982) reported that female rats dosed with ethylene oxide at 7.5 or
 
30 mg/kg/day by gavage for 2 days/week for 3 years developed a d
 
oserelated incidence of local tumors, mainly squamous-cell carcinoma of the
 
forestomach, a tumor commonly seen following long-term gavage
 
administration of irritant chemicals. No tumors were found at sites
 
away from the point of administration.
 
These levels are presented in Table 2-2, and 7.5 mg/kg/day is
 
plotted as the Cancer Effect Level for ethylene oxide in Figure 2-2.
 
2.2.3 Dermal Exposure
 
2.2.3.1 Death
 
No studies were located regarding lethal effects in animals or
 
humans after dermal exposure to ethylene oxide.
 
2.2.3.2 Systemic Effects
 
No studies were located regarding the respiratory, cardiovascular,
 
gastrointestinal, hematological, musculoskeletal, hepatic or renal
 
effects in humans or animals after dermal exposure to ethylene oxide.
 
Dermal/Ocular Effects. Data related to human dermal exposure to
 
ethylene oxide are generally associated with case reports of industrial
 
accidents, some of which occurred in the 1930's and 1940's.
 
Concentrated ethylene oxide evaporates rapidly from the skin and
 
produces a freezing effect, often compared to frostbite, leaving burns
 
ranging from first to third-degree severity (Taylor 1977). Workers
 
drenched with a 1% solution developed large vesiculated blisters (Sexton
 
and Henson 1949). Nausea and vomiting were also reported in this case
 
study, but might have resulted from inhalation of the vapors rather than
 
from dermal contact.
 
A study using human volunteers by Sexton and Henson (1950) showed
 
that the magnitude of skin injury was related to the concentration of
 
ethylene oxide in solution but peaked at about 50%. This was attributed
 
to the rapid evaporation of the more concentrated solutions, which
 
prevented more prolonged skin contact.
 
Case reports of patients whose intact skin or wounds had contact
 
with gauze or other hospital supplies that had been sterilized with
 
ethylene oxide indicated that the observed skin reactions included
 
erythema, blister formation, scaling, crusted ulcerations and second
 
degree burns (Alomar et al. 1981; Hanifin 1971).
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Shupack et al. (1981) demonstrated that human skin reactions to
 
ethylene oxide in patch materials were directly related to the total
 
dose.
 
Cornea1 burns (McLaughlin 1946; Thiess 1963) and cataracts (Gross
 
et al. 1979; Jay et al. 1982) have been reported in cases of
 
occupational exposure to ethylene oxide. Although the cornea1 burns
 
were due to direct ocular contact with ethylene oxide, it was not clear
 
in the cases of cataracts whether they could be attributed to ocular
 
contact with ethylene oxide vapor or were a systemic effect resulting
 
from inhalation of ethylene oxide.
 
Dermal application of ethylene oxide on rabbits and guinea pigs has
 
resulted in hyperemia (the presence of an increased amount of blood),
 
edema (Hollingsworth et al. 1956), and skin irritation (Bruch 1973;
 
Woodard and Woodard 1971).
 
Ocular effects in rabbits after ocular instillation of ethylene
 
oxide solution have been reported as congestion, swelling, discharge,
 
iritis, cornea1 cloudiness, and irritation (McDonald et al. 1977;
 
Woodard and Woodard 1971).
 
2.2.3.3 Immunological Effects
 
Theiss (1963) did not observe skin sensitization in ethylene oxide
 
plant workers (average exposure: 10.4 years) who were challenged with a
 
single dermal application of 1% ethylene oxide. Dermal application
 
studies using human volunteers by Sexton and Henson (1950) and Shupack
 
et al. (1981) however, have provided some evidence that ethylene oxide
 
is a skin sensitizer. A case study of a hospital patient diagnosed wit1
 
allergic contact dermatitis in response to ethylene oxide also suggests
 
skin sensitization (Alomar et al. 1981). However, ethylene chlorhydrin
 
may also have contacted the patient's skin.
 
Skin sensitization studies in guinea pigs by Woodard and Woodard
 
(1971), however, were negative.
 
No other data on the potential immunologic effects of dermal
 
exposure to ethylene oxide were located, and it is not clear if
 
immunological effects are of concern following dermal exposure to
 
ethylene oxide.
 
No studies were located regarding the following health effects in
 
humans or animals after dermal exposure to ethylene oxide:
 
2.2.3.4 Neurological Effects
 
2.2.3.5 Developmental Effects
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2.2.3.6 Reproductive Effects
 
2.2.3.7 Genotoxic Effects
 
2.2.3.8 Cancer
 
No studies were located regarding carcinogenic effects in humans
 
after dermal exposure to ethylene oxide.
 
In a lifetime skin painting study, application of a 10% solution of
 
ethylene oxide to the backs of mice did not result in skin tumors or
 
irritation (Van Duuren et al. 1965).
 
2.3 TOXICOKINETICS
 
2.3.1 Absorption
 
2.3.1.1 Inhalation Exposure
 
In a study of hospital workers by Brugnone et al. (1985), alveolar
 
ethylene oxide concentrations were highly correlated with ambient
 
ethylene oxide concentrations. The average alveolar retention of
 
ethylene oxide was approximately 75% of the ambient concentration.
 
Animal studies have shown that ethylene oxide is rapidly absorbed by the
 
respiratory systems of the rat (Koga et al. 1987; Matsuoka 1988;
 
Nakashima et al. 1987; Tardif et al. 1987), mouse (Cumming et al. 1981;
 
Ehrenberg et al. 1974; Tardif et al. 1987), and rabbit (Tardif et al.
 
1987).
 
2.3.1.2 Oral Exposure
 
No studies were located regarding absorption of ethylene oxide
 
after oral exposure.
 
2.3.1.3 Dermal Exposure
 
No studies were located regarding absorption of ethylene oxide
 
after dermal exposure.
 
2.3.2 Distribution .
 
2.3.2.1 Inhalation Exposure
 
No studies were located regarding the distribution of ethylene
 
oxide in human tissue after inhalation exposure. Ehrenberg et al.
 
(1974) reported that 75 minutes after exposing mice, the highest
 
concentrations of ethylene oxide were observed in the lungs, liver and
 
kidneys. Lesser amounts were found in the spleen, brain and testes.
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Tyler and McKelvey (1982) found that in rats administered
 
14C-ethylene oxide, the highest concentrations of 14C-activity were found
 
in the urinary bladder, liver, packed blood cells, and adrenal glands,
 
with the lowest concentration found in the fat.
 
Tyler (1983) evaluated the fate of ethylene oxide in pre-exposed
 
rats and their respective controls. Urine, feces and expired air were
 
collected during and 18 hours after exposure to 14C-ethylene oxide.
 
There were no significant differences in the concentration of
 
radioactivity in either group of animals, except that the radioactivity
 
associated with the red blood cells was 1.3 times greater in animals
 
that were not pre-exposed.
 
2.3.2.2 Oral Exposure
 
No studies were located regarding distribution of ethylene oxide
 
after oral exposure.
 
2.3.2.3 Dermal Exposure
 
No studies were located regarding distribution of ethylene oxide
 
after dermal exposure.
 
2.3.3 Metabolism
 
The metabolism of ethylene oxide is not completely known. Data
 
from animal studies indicate two possible pathways for the metabolism of
 
ethylene oxide: hydrolysis to ethylene glycol and glutathione
 
conjugation to form mercapturic acid and meththio-metabolites. Martis
 
et al. (1982) identified 1,2-ethanediol (ethylene glycol), a hydrolysis
 
product, in the plasma and urine of beagle dogs one hour after intravenous
 
administration of ethylene oxide. Ethylene glycol was the major
 
metabolite of ethylene oxide, with 7 to 24% of the administered dose
 
excreted in the urine within 24 hours. Koga et al. (1987) identified
 
ethylene glycol, 2-hydroxymercapturic acid, 2-methylthioethanol and
 
2-mercaptoethanol as metabolites in the urine of rats.
 
Tardi.f et al. (1987) studied the qualitative and quantitative
 
urinary disposition of some metabolites of ethylene oxide in three
 
rodent species: mouse, rat and rabbit. Important differences were
 
observed among the three species in the urinary metabolic disposition of
 
ethylene oxide. After an intravenous injection of ethylene oxide at
 
20 mg/kg, mice excreted significantly higher quantities of
 
N-acetyl-S-(2-hydroxyethyl)-L-cysteine, S-(2-hydroxyethyl)-L-cysteine,
 
S-carboxymethyl-L-cysteine and ethylene glycol (8.3, 5.8, 1.9 and 3.3%
 
of the administered dose, respectively, in 24 hours), whereas in rats,
 
only N-acetyl-S- (2-hydroxyethyl)-L-cysteine (31%) and ethylene glycol
 
(6%) were apparent. In contrast, the rabbits were found to excrete only
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ethylene glycol (2%). This study further revealed species-related
 
differences in the urinary excretion of N-acetyl-S-(2-hydroxyethyl)­
L-cysteine and ethylene glycol during the two collection periods. The
 
observed differences among the three species in the metabolic
 
disposition of ethylene oxide were found to be qualitatively independent
 
of the route of exposure, (i.e., inhalation at 200 ppm or intravenous
 
injection of 20 or 60 mg/kg). These results suggest that care should be
 
exercised when using any single animal species as a model for human
 
disposition of ethylene oxide.
 
Tyler (1983) evaluated the fate of ethylene oxide in pre-exposed
 
rats and their respective controls. Urine, feces and expired air were
 
collected during and 18 hours after exposure to 14C-ethylene oxide.
 
There were no significant differences between the non-pre-exposed or
 
pre-exposed animals in the metabolic profiles. The data indicate that
 
prolonged exposure of rats to ethylene oxide has little effect on the
 
metabolism of the chemical.
 
Matsuoka (1988) reported that in rats exposed to ethylene oxide for
 
three months, the cytochrome P-450 enzyme systems in the lung and brain
 
were not affected. However, hepatic cytochrome P-450 and protoheme
 
decreased by 28% and 19%, respectively. Hepatic total microsomal
 
protein, cytochrome b5, NADPH-cytochrome c reductase and NADH-ferricyanide
 
reductase were not affected. The activity of hepatic heme
 
oxygenase showed a two-fold increase. These results suggest that the
 
heme moiety of hepatic cytochrome P-450 was primarily affected by
 
exposure of ethylene oxide and the cellular heme balance in liver was
 
altered.
 
Nakashima et al. (1987) found that in rats exposed to ethylene
 
oxide for 12 weeks, the concentration of the reduced form of glutathione
 
(GSH) in the liver was not significantly different from that of
 
controls. However, the hepatic GSH levels in rats subjected to a 4 hour
 
exposure to a high concentration of ethylene oxide (2,500 ppm) were
 
markedly decreased. These data suggest the involvement of glutathione
 
in the detoxication of ethylene oxide, at least in the rat.
 
McKelvey and Zemaitis (1986) exposed rats and mice to different,
 
atmospheric concentrations of ethylene oxide for 4 hours. In mice
 
sacrificed immediately after exposure to ethylene oxide, there was a
 
concentration-related decrease in the GSH levels of all tissues
 
examined. Similar findings were obtained in rats immediately after
 
exposure to ethylene oxide, except that blood GSH levels were not
 
affected at any exposure concentration. In both species, lung and liver
 
GSH levels were depressed at all exposure concentrations. Twenty-four
 
hours after exposure to ethylene oxide, the GSH concentrations of rat
 
bone marrow and testis had not returned to control levels. Only blood
 
GSH levels remained depressed in mice 48 hours after exposure to
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ethylene oxide. The results indicate a marked species difference
 
between rats and mice regarding the effects of ethylene oxide exposure
 
on blood GSH levels.
 
2.3.4 Excretion
 
2.3.4.1 Inhalation Exposure
 
No studies were located regarding excretion of ethylene oxide in
 
humans after inhalation exposure.
 
Tyler and McKelvey (1982) found that in the rat, the primary route
 
of 14C-ethylene oxide elimination was urine (mean value of 59% recovered
 
14C-activity), followed by expired CO, (12%), feces (4.5%), and expired
 
ethylene oxide (1%). Cumming et al. (1981) reported that ethylene oxide
 
was rapidly eliminated by mice that had been exposed to radio-labeled
 
ethylene oxide. Ehrenberg et al. (1974) reported that in mice ethylene
 
oxide has a biological half-life of approximately 9 minutes. Seventy-eight
 
percent of the administered dose was eliminated within 48 hours,
 
suggesting rapid urinary excretion. Filser and Bolt (1984) found that
 
ethylene oxide administered in a closed-system inhalation chamber
 
exhibited first-order elimination kinetics.
 
Tyler (1983) evaluated the fate of ethylene oxide in pre-exposed
 
rats and their respective controls. Urine, feces and expired air were
 
collected during and 18 hours after exposure to 14C-ethylene oxide.
 
There were no significant differences between the nonpre-exposed or
 
pre-exposed animals in the routes of elimination.
 
2.3.4.2 Oral Exposure
 
No studies were located regarding excretion of ethylene oxide after
 
oral exposure.
 
2.3.4.3 Dermal Exposure
 
No studies were located regarding excretion of ethylene oxide after
 
dermal exposure.
 
2.4 RELEVANCE TO PUBLIC HEALTH
 
As discussed previously in Section 2.2, the main route of exposure
 
to ethylene oxide in humans is via inhalation, and the main health
 
effects are central nervous system depression and irritation of the eyes
 
and mucous membranes.
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Reproductive effects have been observed in animal studies but there
 
is no clear evidence of these effects in humans. Similarly, ethylene
 
oxide is clearly a carcinogen in animals, and epidemiological studies in
 
humans have shown limited evidence of carcinogenic effects in
 
occupationally exposed populations.
 
Death. The available reports (Gardner et al. 1989; Greenberg
 
et al. 1989) indicate that there is no increased incidence of human
 
death in association with ethylene oxide exposure. In mice, four-hour
 
exposures to 800 ppm resulted in a high rate of mortality (80-100%)
 
whereas 400 ppm exposures for 14 days did not result in death (NTP
 
1987). A level of 100 ppm for two years did not result in increased
 
lethality of mice (NTP 1987) or monkeys (Lynch et al. 1984a).
 
Based on the available data, lethality due to inhalation of
 
ethylene oxide may not be a health concern in occupational settings,
 
except with the use of damaged or leaking equipment.
 
Systemic Effects. Bronchitis, pulmonary edema and emphysema have
 
been reported in workers after acute high-level exposure (Theiss 1963),
 
but respiratory problems have not been reported to occur with chronic
 
exposure (Joyner 1964). Evidence of the potential for respiratory
 
irritation resulting from ethylene oxide inhalation comes mainly from
 
animal studies.
 
Based on data in mice, it appears that exposure level is more
 
important than duration of exposure with respect to respiratory effects.
 
Mice exposed to 200 ppm or more for 14 days suffered from rhinitis, loss
 
of polarity of olfactory and respiratory epithelial cells, epithelial
 
necrosis, loss of cilia and accumulation of purulent exudate. These
 
lesions were not seen by the same investigators in mice exposed to
 
100 ppm for two years NTP (1987).
 
Thus it appears that, at least in animals and possibly in humans,
 
there is a critical concentration of ethylene oxide that is necessary to
 
elicit respiratory irritation and the resulting lesions.
 
Dermal and ocular irritation have been reported in several case
 
studies of individuals occupationally exposed to ethylene oxide. Dermal
 
contact results in skin burns of varying severity depending on the
 
concentration of ethylene oxide and the length of contact (Sexton and
 
Henson 1949; Shupack et al. 1981). Cornea1 burns have been reported in
 
workers whose eyes have been splashed with ethylene oxide in solution or
 
blasted by the vapor (McLaughlin 1946; Thiess 1963).
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Cataracts have also been associated with occupational exposure to
 
ethylene oxide when workers were exposed to a leaky sterilizer (Gross
 
et al. 1979; Jay et al. 1982). It is not clear whether the development
 
of cataracts was a response to direct ocular contact with the vapor or
 
was a systemic response to inhaled ethylene oxide.
 
Dermal application studies in animals have confirmed that ethylene
 
oxide is a dermal irritant (Bruch 1973; Hollingsworth et al. 1956;
 
Woodard and Woodard 1971) and ocular irritant (McDonald et al. 1977;
 
Woodard and Woodard 1971).
 
Immunological Effects. There is no clear evidence in animals or
 
humans that exposure to ethylene oxide via the inhalation, oral, or
 
dermal route is associated with immunological effects.
 
Neurological Effects. Central nervous system effects are
 
frequently associated with human exposure to ethylene oxide in
 
occupational settings. Headache, nausea and vomiting have been reported
 
for more than fifty years (Blackwood and Erskine 1938; von Oettingen
 
1939; Sexton and Henson 1949). Reliable exposure levels are generally
 
not available in these cases. Peripheral neuropathy, impaired hand-eye
 
coordination and memory loss have been reported in more recent case
 
studies of chronically-exposed workers (Crystal et al. 1988; Estrin
 
et al. 1987; Kuzuhara et al. 1983; Zampollo et al. 1984) at estimated
 
average exposure levels as low as 3 ppm (with possible short-term peaks
 
as high as 700 ppm).
 
In studies using several animal species at moderately high levels
 
of ethylene oxide (200-375 ppm) for 6 to 7 months, hind leg paralysis
 
and atrophy, abnormal knee and extensor reflexes, and diminished pain
 
perception were reported (Hollingsworth et al. 1956). Even levels of
 
50 ppm for l0-11 weeks resulted in hunched posture, reduced locomotion,
 
and abnormal righting reflexes in mice (Snellings et al. 1984a). A
 
g-month exposure to 250 ppm resulted in distal axonal degeneration of
 
myelinated fibers in both sural nerves and gracile fascicles in rats
 
(Ohnishi et al. 1986). Chronic exposures to ethylene oxide at 100 ppm
 
resulted in slight demyelination of the brains of monkeys and exposure
 
to 500 ppm resulted in brain lesions in rats (Lynch et al. 1984a).
 
These results raise concerns that similar morphological effects may
 
occur in humans.
 
Based on the body of available data from both human and animal
 
studies, the neurotoxic effects of ethylene oxide are an occupational
 
health concern for a wide range of exposure levels and durations. Both
 
chronic low level exposure associated with years of normal employment
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conditions, as well as the brief or even protracted exposure duration to
 
high ethylene oxide levels due to industrial accidents or faulty
 
equipment, can lead to a broad spectrum of adverse neurological effects.
 
Developmental Effects. No data on the potential human
 
developmental effects of ethylene oxide exposure have been located and
 
the available data in animal studies (Hackett et al. 1982; Snellings
 
et al. 1982a) do not indicate that inhalation exposure to ethylene oxide
 
is associated with teratogenic effects. However, embryo and fetal
 
toxicity were reported in the offspring of rats exposed to 100 ppm
 
during gestation; the neonates were smaller in both length and weight
 
and had reduced ossification of the skull and sternebrae (Snellings
 
et al. 1982a). Intravenous administration of ethylene oxide to pregnant
 
mice resulted in decreased fetal weight and increases in dead and
 
resorbed fetuses and in fetal malformations (La Borde and Kimmel 1980).
 
Therefore, the offspring of humans exposed to ethylene oxide may be at
 
risk for teratogenicity and fetal and embryo toxicity.
 
Reproductive Effects. Based on the available human and animal
 
studies, inhalation exposure to ethylene oxide is associated with
 
numerous adverse reproductive effects in both males and females. In an
 
epidemiological study, Hemminki et al. (1982) reported that the
 
spontaneous abortion rates of ethylene oxide sterilizer operators in
 
Finnish hospitals were significantly higher than those of non-exposed
 
workers. Exposure levels were estimated to be as low as 0.1 to 0.5 ppm.
 
However, there were various limitations to the interpretation of this
 
study, as described in Section 2.2.1.6. Abrahams (1980) reported
 
decreased sperm counts in ethylene oxide workers, but as stated
 
previously, the small number of sperm samples obtained for analysis
 
precluded firm interpretation of the findings.
 
Decreased numbers of implantation sites have been reported in rats
 
exposed to ethylene oxide at 100 ppm during gestation (Snellings et al.
 
1982b). Reproductive effects in males have been reported in at least
 
three species of animals. Decreased testicular weights and testicular
 
degeneration have been observed in rats and guinea pigs exposed to
 
ethylene oxide for 6 to 7 months at 204 and 357 ppm, respectively
 
(Hollingsworth et al. 1956). In monkeys exposed at 50 ppm for two
 
years, decreased sperm concentration and drive range and reductions in
 
testicular and epididymal weights have been reported (Lynch et al.
 
1984a). An autoradiography study in mice by Appelgren et al. (1977)
 
indicates that ethylene oxide or one of its degradation products has
 
access to the male gonads (testes and epididymis) in this species within
 
four hours of intravenous exposure.
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The potential for adverse reproductive effects is apparently an
 
area which warrants attention in terms of human exposure to ethylene
 
oxide.
 
Genotoxic Effects. Ethylene oxide has been demonstrated to be
 
genotoxic in a wide variety of prokaryotic and eukaryotic test systems.
 
A summary of the available in vitro genotoxicity studies for ethylene
 
oxide is presented in Table 2-3.
 
Peripheral blood studies of exposed workers have indicated that
 
ethylene oxide exposure is associated with an elevated incidence of
 
chromosomal aberrations including breaks, gaps, and exchanges and
 
supernumerary chromosomes (Galloway et al. 1986; Pero et al. 1981; Sarto
 
et al. 1984a; Theiss et al. 1981). An increased incidence of sister
 
chromatid exchange (SCE) in the peripheral lymphocytes of ethylene oxide
 
workers has also been reported by Galloway et al. (1986), Garry et al.
 
(1979), Lambert and Lindblad (1980), Sarto et al. (1984 and 1984b) and
 
Yager et al. (1983).
 
Increased and persistent elevations of SCE have also been observed
 
in the peripheral blood lymphocytes of monkeys, (Kelsey et al. 1988;
 
Lynch et al. 1984a) exposed to ethylene oxide for two years, providing
 
additional concern for the carcinogenic potential of this compound for
 
humans exposed via inhalation.
 
Cancer. There is evidence from both human and animal studies that
 
inhalation exposure to ethylene oxide can result in a wide range of
 
carcinogenic effects. Epidemiological studies in ethylene oxide factory
 
workers and sterilizer operators have indicated that leukemia, stomach
 
cancer (Hogstedt et al. 1979, 1986) pancreatic cancer and Hodgkin's
 
disease (Morgan et al. 1981) were elevated in exposed individuals. As
 
described in Section 2.2.1.8, the Hogstedt data are viewed as having
 
certain limitations. Other studies (Gardner et al. 1989; Greenberg
 
et al. 1990; Kiesselbach et al. 1990) have not found these associations.
 
Inhalation studies in animals have resulted in mononuclear cell
 
leukemia, peritoneal mesotheliomas, and various brain tumors in rats
 
(Lynch et al. 1984b; Snellings et al. 1984b) at levels as low as 33 ppm.
 
Lung tumors, tumors of the harderian gland, malignant lymphomas and
 
uterine and mammary gland tumors were also found in mice (NTP 1987).
 
In the only located animal study using the oral route, female rats
 
dosed with ethylene oxide by gavage at 7.5 mg/kg/day developed squamous
 
cell carcinomas of the forestomach (the site of application) only, but
 
not at any distal sites (Dunkelberg 1982). Ethylene oxide is ranked as
 
a Group Bl carcinogen (i.e., a probable human carcinogen) by EPA's
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Carcinogen Assessment Group (IRIS 1989) and a 2A carcinogen by IARC
 
(1987). These classifications are based on adequate evidence in animal
 
studies but limited or inadequate evidence in humans (EPA 1985a).
 
Ethylene oxide was not found to cause skin tumors in a skin painting
 
study using mice (Van Duuren et al. 1965).
 
Data from in vitro studies indicate that ethylene oxide is
 
mutagenic in several prokaryotic and eukaryotic systems.
 
Based on the available data, carcinogenicity is an area of major
 
concern in relation to humans chronically exposed to ethylene oxide via
 
inhalation in occupational settings.
 
2.5 BIOMARKERS OF EXPOSURE AND EFFECT
 
Biomarkers are broadly defined as indicators signaling events in
 
biologic systems or samples. They have been classified as markers of
 
exposure, markers of effect, and markers of susceptibility (NAS/NRC
 
1989).
 
A biomarker of exposure is a xenobiotic substance or its
 
metabolite(s) or the product of an interaction between a xenobiotic
 
agent and some target molecule or cell that is measured within a
 
compartment of an organism (NAS/NRC 1989). The preferred biomarkers of
 
exposure are generally the substance itself or substance-specific
 
metabolites in readily obtainable body fluid or excreta. However,
 
several factors can confound the use and interpretation of biomarkers of
 
exposure. The body burden of a substance may be the result of exposures
 
from more than one source. The substance being measured may be a
 
metabolite of another xenobiotic (e.g., high urinary levels of phenol
 
can result from exposure to several different aromatic compounds).
 
Depending on the properties of the substance (e.g., biologic half-life)
 
and environmental conditions (e.g., duration and route of exposure), the
 
substance and all of its metabolites may have left the body by the time
 
biologic samples can be taken. It may be difficult to identify
 
individuals exposed to hazardous substances that are commonly found in
 
body tissues and fluids (e.g., essential mineral nutrients such as
 
cower, zinc and selenium). Biomarkers of exposure to ethylene oxide
 
are discussed in Section 2.5.1.
 
Biomarkers of effect are defined as any measurable biochemical,
 
physiologic, or other alteration within an organism that, depending on
 
magnitude, can be recognized as an established or potential health
 
impairment or disease (NAS/NRC 1989). This definition encompasses
 
biochemical or cellular signals of tissue dysfunction (e.g., increased
 
liver enzyme activity or pathologic changes in female genital epithelium
 
cells), as well as physiologic signs of dysfunction such as increased
 
blood pressure or decreased lung capacity. Note that these markers are
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often not substance specific. They also may not be directly adverse,
 
but can indicate potential health impairment (e.g., DNA adducts).
 
Biomarkers of effects caused by ethylene oxide are discussed in
 
Section 2.5.2.
 
A biomarker of susceptibility is an indicator of an inherent or
 
acquired limitation of an organism's ability to respond to the challenge
 
of exposure to a specific xenobiotic. It can be an intrinsic genetic or
 
other characteristic or a preexisting disease that results in an
 
increase in absorbed dose, biologically effective dose, or target tissue
 
response. If biomarkers of susceptibility exist, they are discussed in
 
Section 2.7, "POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE."
 
2.5.1 Biomarkers Used to Identify or Quantify Exposure to Ethylene

 Oxide
 
Ethylene oxide can be measured in blood (Bailey et al. 1987;
 
Brugnone et al. 1986; Farmer et al. 1986) and alveolar air (Brugnone
 
et al. 1986). Because ethylene oxide is very reactive in biological
 
systems, it is usually necessary to measure its addition products (e.g.,
 
N-(2-hydroxyethyl)histidine or N-(2-hydroxyethyl)valine) in blood.
 
However, based on the currently available information, the levels
 
of these substances in biological media cannot be used to calculate or
 
estimate corresponding levels of exposure to ethylene oxide.
 
2.5.2 Biomarkers Used to Characterize Effects Caused by Ethylene Oxide
 
There are currently no subtle or sensitive biomarkers of effects
 
associated with ethylene oxide.
 
2.6 INTERACTIONS WITH OTHER CHEMICALS
 
No data have been located that identify the interactions of
 
ethylene oxide with other chemicals in the environment.
 
2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
 
No population has been identified that is more at risk from
 
ethylene oxide exposure based on biological differences.
 
2.8 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of
 
the Public Health Service) to assess whether adequate information on the
 
health effects of ethylene oxide is available. Where adequate
 
information is not available, ATSDR, in conjunction with the National
 
 44
 
2. HEALTH EFFECTS
 
Toxicology Program (NTP), is required to assure the initiation of a
 
program of research designed to determine the health effects (and
 
techniques for developing methods to determine such health effects) of
 
ethylene oxide.
 
The following categories of possible data needs have been
 
identified by a joint team of scientists from ATSDR, NTP, and EPA. They
 
are defined as substance-specific informational needs that, if met would
 
reduce or eliminate the uncertainties of human health assessment. In
 
the future, the identified data needs will be evaluated and prioritized,
 
and a substance-specific research agenda will be proposed.
 
2.8.1 Existing Information on the Health Effects of Ethylene Oxide
 
The existing data on health effects of inhalation, oral, and dermal
 
exposure of humans and animals to ethylene oxide are summarized in
 
Figure 2-3. The purpose of this figure is to illustrate the existing
 
information concerning the health effects of ethylene oxide. Each dot
 
in the figure indicates that one or more studies provide information
 
associated with that particular effect. The dot does not imply anything
 
about the quality of the study or studies. Gaps in this figure should
 
not be interpreted as "data needs" information.
 
As indicated in Figure 2-3, most of the available information on
 
the health effects of ethylene oxide is related to the inhalation route.
 
Most of the data on humans are related to case studies based on normal
 
or accidental occupational exposure.
 
Studies in animals have been more comprehensive, but as described
 
in the previous section, much of the information is considered to be
 
limited in its usefulness for a variety of reasons.
 
2.8.2 Identification of Data Needs
 
Acute-Duration Exposure. Information on acute-duration exposure of
 
humans to ethylene oxide indicates that irritation reactions involving
 
the mucous membranes of the respiratory system and the skin are the
 
result of inhalation and dermal exposure, respectively. Available
 
information in animals is limited to lethality data in mice via the
 
inhalation route and in rats via the oral route, as well as information
 
on dermal/ocular effects after local administration. The data were not
 
considered to be adequate to calculate an MRL by any route. Further
 
animal studies using acute-duration inhalation exposure to ethylene
 
oxide may be useful in identifying the mechanism of lethality. This
 
information would be relevant to the safety of workers in industrial or
 
hospital settings. Data on acute-duration exposure via the oral route
 
would also be helpful. Some of the currently available studies were
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conducted 30 to 50 years ago, and improvements in experimental
 
technology since then may result in more accurate estimates of exposure
 
levels and analysis of results.
 
Intermediate-Duration Exposure. The currently available data on
 
intermediate-duration exposure to ethylene oxide in humans also indicate
 
that irritation reactions are the major effects resulting from
 
inhalation or dermal exposure. Data in animals via inhalation are
 
useful in assessing its potential effects on a variety of organ systems.
 
An MRL for renal effects in mice exposed via inhalation has been
 
calculated for this duration period. Although intermediate-duration
 
studies via the oral and dermal routes are not currently available,
 
there is no indication that they would be a valuable contribution to the
 
data base for this chemical.
 
Chronic-Duration Exposure and Cancer. Studies are available for
 
this duration period for both humans and animals exposed via inhalation
 
and for animals exposed via the oral route. However, the data were not
 
considered to be adequate to calculate an MRL for any route of exposure.
 
Data on the carcinogenic potential of ethylene oxide in
 
occupationally exposed humans are inconclusive, with both positive and
 
negative results reported in the available studies. The currently
 
available studies on the chronic exposure of various animal species to
 
ethylene oxide have established that this chemical is clearly
 
carcinogenic via the inhalation route. If it were determined that
 
ethylene oxide residues still remain in or on various agricultural
 
commodities when they are consumed by humans, a chronic feeding study in
 
animals might also be useful. Also, further epidemiologic assessments
 
of the carcinogenic and other health effects in occupationally exposed
 
humans, including dermal effects, would also provide valuable data.
 
Based on the results of such studies, dermal carcinogenicity studies in
 
animals might be relevant to the welfare of occupationally exposed
 
workers.
 
Genotoxicity. The genotoxicity of ethylene oxide has been
 
established in a number of in vitro tests using various prokaryotic and
 
eukaryotic systems as well as in vivo studies of human peripheral blood.
 
Further studies in this area do not currently appear to be necessary.
 
Reproductive Toxicity. Available data on ethylene oxide's
 
reproductive effects on occupationally exposed males are considered
 
inconclusive; further investigation of these individuals would be
 
extremely useful. Further data on occupationally exposed women would
 
also be helpful since the currently available data are limited to a
 
single study of spontaneous abortions in Finnish hospital workers. The
 
currently available reproductive toxicity data from inhalation studies
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in animals indicate that this may be an area of concern for inhalation
 
exposure to ethylene oxide. Reproductive toxicity studies in animals
 
via the oral route may also be useful. Studies using the dermal route
 
would probably not be useful unless systemic absorption via skin
 
application is first demonstrated.
 
Developmental Toxicity. There are no data on developmental
 
toxicity in the offspring of humans exposed to ethylene oxide via
 
inhalation, oral, or dermal routes. The currently available data in
 
rats indicate that fetal and embryo toxicity can result from inhalation
 
exposure to ethylene oxide, and fetal abnormalities have been increased
 
in studies using intravenous administration. No studies in this area
 
using oral or dermal exposure have been located. Studies to assess the
 
developmental effects of exposure to ethylene oxide via the inhalation
 
and the oral routes would be useful in assessing the potential risks to
 
offspring of persons exposed to this chemical in the workplace or in the
 
vicinity of hazardous waste sites. Studies using the dermal route would
 
probably not be useful unless systemic absorption can be demonstrated to
 
result from dermal application.
 
Immunotoxicity. The currently available information does not
 
indicate that this is an area of potential concern for ethylene oxide
 
exposure via any route.
 
Neurotoxicity. Ethylene oxide has been established as a neurotoxin
 
in both humans and animals via the inhalation route; therefore, further
 
studies using this route would not appear to be a priority. Studies in
 
animals using the oral route may provide useful information if it is
 
first determined that ethylene oxide residues still remain in or on
 
agricultural commodities when they are consumed by humans. Studies
 
using the dermal route would probably not be useful unless systemic
 
absorption via skin application can first be demonstrated.
 
Epidemiological and Human Dosimetry Studies. Although ethylene
 
oxide has been shown to be toxic to humans in several studies, the
 
related air concentrations have not been sufficiently established.
 
Estimates provided in some studies range from as low as 0.1 ppm for
 
chronic exposure to as high as 700 ppm for intermediate exposure.
 
Dosimetry studies would be valuable in providing retrospective insights
 
into the data reported in human case and epidemiological studies as well
 
as in attempting to determine the most relevant range of exposures at
 
which to conduct any further animal studies. Epidemiological studies of
 
occupationally exposed persons would be useful in determining the risks
 
of cancer, reproductive effects, and neurological effects associated
 
with long-term exposure to ethylene oxide.
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Biomarkers of Exposure and Effect. Measurement of ethylene oxide
 
or its addition products, N-(Z-hydroxyethyl)histidine or N­
(2-hydroxyethyl)valine, in blood may provide an adequate qualitative
 
indication of recent exposure to ethylene oxide. The development of
 
methods that could be used to calculate or estimate levels of exposure
 
to ethylene oxide from the levels of these substances in biological
 
fluids would be extremely useful.
 
There are currently no subtle or sensitive biomarkers of effects
 
caused by ethylene oxide. It would be useful to have information to
 
correlate levels of ethylene oxide addition products in blood or other
 
biological media with the onset of adverse health effects.
 
Absorption, Distribution, Metabolism and Excretion. The absorption
 
of ethylene oxide administered via inhalation has been extensively
 
studied in humans and several species of animals. Data on its
 
absorption when administered via the oral and dermal routes would also
 
be valuable.
 
Data are available on the distribution of ethylene oxide after
 
inhalation by rats and mice. Studies that provide information on its
 
distribution after oral and dermal administration would also be helpful.
 
The metabolism of ethylene oxide is not completely known. Studies to
 
further characterize the two possible pathways for the metabolism of
 
ethylene oxide, hydrolysis and glutathione conjugation, and to identify,
 
if possible, the species in which metabolism most resembles that in
 
humans would be useful. It may also be helpful to characterize
 
unidentified urinary metabolites that have been reported in several
 
studies.
 
Excretion data are available only for rats and mice exposed to
 
ethylene oxide via inhalation. Studies using the oral and dermal routes
 
may also provide useful information.
 
Comparative Toxicokinetics. The available toxicokinetic studies
 
are limited and it is not possible to determine if there are any major
 
differences in the kinetics of ethylene oxide absorption, distribution,
 
metabolism or excretion across species. It would be useful to
 
investigate patterns of distribution, to identify target organs, to
 
measure rates of excretion in several species, and to identify blood
 
metabolites in humans and animals in order to understand what, if any,
 
relationships exist. Studies in this area would also be helpful in
 
putting the results of all available toxicity studies into perspective
 
in terms of their relevance to the potential human health effects of
 
ethylene oxide under similar conditions of exposure.
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2.8.3 On-going Studies
 
The NTP Annual Plan for FY 1988 (NTP 1988a) indicated that ethylene
 
oxide testing was scheduled to be ongoing or completed in the following
 
areas:
 
• 	 In vitro microbial testing for mutagenesis and genetic toxicity
 
• 	 In vitro Chinese hamster ovary assay to detect chromosomal

 aberrations and sister chromatid exchange
 
• 	 Drosophila sex-linked lethality assay
 
• 	 Neurological and behavioral toxicity testing
 
• 	 Inhalation testing in mice and rats to study pulmonary and

 immunologic toxicity
 
In addition, the Ethylene Oxide Industry Council (EOIC), a panel of
 
the Chemical Manufacturers Association's CHEM STAR Division, has plans
 
to develop, through the Chemical Industry Institute of Toxicology
 
(CIIT) , a Physiologically-Based Pharmacokinetic (PB-PK) model for the
 
metabolism, disposition and macromolecular reactivity of the ethylene
 
oxide. The PB-PK model is intended to permit extrapolation to predict
 
tissue exposures from various ethylene oxide exposure scenarios and in a
 
variety of animal species, including humans. Eventually, a
 
comprehensive risk assessment will combine the PB-PK model for chemical
 
disposition and tissue dosimetry of DNA adducts with biologically-based
 
descriptions of the cancer process. The completed PB-PK model will be
 
used to interpret the rodent bioassay study results, to support a human
 
risk assessment for exposure, and to interpret exposure assessment
 
studies based on the concentration of hemoglobin adducts in exposed
 
persons.
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3. CHEMICAL AND PHYSICAL INFORMATION
 
3.1 CHEMICAL IDENTITY
 
Tables 3-l lists common synonyms, trade names, and other pertinent
 
identification information for ethylene oxide.
 
3.2 PHYSICAL AND CHEMICAL PROPERTIES
 
Table 3-2 lists important physical and chemical properties of
 
ethylene oxide.
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4.1 PRODUCTION
 
Ethylene oxide is a major industrial chemical and is one of the 25
 
highest production volume chemicals in the United States There was a
 
gradual increase in the production volume of ethylene oxide in recent
 
years from 1,906,800 kkg (metric tons) in 1973 to a peak of
 
2,610,500 kkg in 1979, and then a gradual decrease to 2,172,530 kkg in
 
1987.
 
Ethylene oxide is produced by 12 chemical companies in the United
 
States in four states; one plant is in Illinois, one in Delaware, four
 
in Louisiana, and six in Texas. The manufacturers of ethylene oxide are
 
also the major users and distributors of the compound.
 
In the United States, all ethylene oxide is produced by the direct
 
oxidation of ethylene by air or oxygen in the presence of a silver oxide
 
catalyst. Another commercial production method, reaction of ethylene
 
chlorohydrin with potassium hydroxide or calcium oxide, was phased out
 
by 1980 (EPA 1985a; SRC 1982; SRI 1984, 1988; USITC 1988; WHO 1985).
 
4.2 IMPORT
 
Imports of ethylene oxide are relatively small, with amounts
 
increasing from 1982 to 1984 from 4,300 kkg to 5,600 kkg. Exports of
 
ethylene oxide increased substantially over the same period, from
 
1,500 kkg in 1982 to 11,200 kkg in 1984 (SRI 1984).
 
4.3 USE
 
Over 99% of the ethylene oxide produced in the United States is
 
used as a chemical intermediate for the production of various chemicals,
 
while less than 1% is used as a sterilant or fumigant. Ethylene oxide
 
is used captively by manufacturers to produce ethylene glycol (64% of
 
ethylene oxide consumption), non-ionic surfactants (11%), glycol ethers
 
(7%), higher glycols (10%), ethanolamines (7%), and miscellaneous
 
chemicals (l%), including choline, polyether polyols, and hydroxyethyl
 
starch. These chemicals are found in antifreeze, textiles, detergents,
 
solvents, polyurethane foam, medicinals, adhesives, and other products.
 
Relatively small amounts of ethylene oxide are used as a fumigant,
 
a sterilant for food (spices) and cosmetics, and in hospital
 
sterilization of surgical equipment and plastic devices that cannot be
 
sterilized by steam. At one time, ethylene oxide was used in the
 
production of acrylonitrile, but that process was discontinued in 1966
 
(EPA 1984a, 1985a; NIOSH 1981; SRC 1982; SRI 1984; WHO 1985).
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4.4 DISPOSAL
 
Because ethylene oxide is listed as a hazardous substance, disposal
 
of wastes containing this compound is controlled by a number of federal
 
regulations (see Chapter 7). Restrictions are proposed for land
 
disposal of ethylene oxide.
 
The production processes for ethylene oxide do not generate solid
 
wastes and the waste waters are treated or recycled. The production
 
process is a closed system; however, vent gases and fugitive emissions
 
may contain some ethylene oxide. Waste gases may be removed from the
 
air by scrubbers. Wastes containing ethylene oxide may be incinerated
 
by rotary kiln or fluidized bed incineration methods (EPA 1989; HSDB
 
1988; SRC 1982; WHO 1985).
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5.1 OVERVIEW
 
Ethylene oxide is a gas used in the production of other synthetic
 
chemicals such as ethylene glycol. Gaseous releases of ethylene oxide
 
to the environment are the result of uncontrolled industrial emissions.
 
Less than 1% of the industrial production of ethylene oxide is used as a
 
fumigant and sterilizing agent for a variety of purposes and materials
 
which include hospital equipment and certain food.
 
Ethylene oxide degrades in both the air and natural water via
 
radical formation and hydrolysis, leading to the formation of glycols,
 
and halogenated alcohols (in the presence of sodium chloride), which in
 
turn degrade into simpler molecules such as carbon dioxide and water.
 
The half-lives of these reactions range from a few hours to less than 15
 
days, depending on environmental conditions. UV-catalyzed oxidation (in
 
the presence of oxygen and nitrogen dioxide) may also account for some
 
of the ethylene oxide lost in the atmosphere. Ethylene oxide also
 
degrades in wastewater treatment systems with a half-life of about 20
 
days.
 
No data are available on the fate of ethylene oxide in soil.
 
Nonetheless, this chemical is expected to either volatilize or be
 
leached due to its high vapor pressure and infinite solubility in water.
 
Soil organisms may also convert it to glycols.
 
Data on the levels of ethylene oxide in the environment are very
 
limited. There are no data to indicate that ethylene oxide is a common
 
constituent of air or water sources of any type in any geographic
 
location within the United States. Fumigated foods and sterilized
 
hospital equipment may have initially high levels of ethylene oxide,
 
which dissipate and/or degrade into other products within a few days.
 
There are no data on ethylene oxide bioaccumulation in marine organisms.
 
No data are available to determine the general population's
 
exposure levels to ethylene oxide. Environmental exposures may include
 
ethylene oxide from car exhaust and tobacco smoke. The populations
 
with potentially higher than average risk of exposure to ethylene oxide
 
include sterilization technicians and industrial workers involved in the
 
manufacture and/or use of ethylene oxide.
 
5.2 RELEASES INTO THE ENVIRONMENT
 
5.2.1 Air
 
Ethylene oxide is a synthetically produced gas used primarily in
 
the production of other chemicals by the chemical industry. As a
 
result, most of the releases of ethylene oxide to the atmosphere occur
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during its storage and handling in industrial settings. Industrial
 
emissions of ethylene oxide are due to uncontrolled fugitive emissions
 
or venting with other gases. Estimates of ethylene oxide losses during
 
production range from 1.3 to 3 million pounds (590 to 1,360 kkg) for
 
1978 and 1980, respectively, as reported in Bogyo et al. (1980). The
 
same report indicated that losses of ethylene oxide during storage might
 
have been about 143,000 pounds (65 kkg) annually.
 
Other sources of ethylene oxide air emissions include its
 
production from combustion of hydrocarbon fuels and its release from
 
commodity-fumigated materials, estimated to be about 10 million pounds
 
(4,500 kkg) annually (Bogyo et al. 1980), and losses during disinfection
 
of hospital equipment.
 
Additional nonquantified sources of air emission of ethylene oxide
 
may be bacterial degradation products, photochemical smog, cigarette
 
smoke and hydrocarbon combustion (Bogyo et al. 1980). Barnard and Lee
 
(1972) and Bogyo et al. (1980) reported finding ethylene oxide in the
 
products of n-pentane combustion, but specific concentrations were not
 
given. EPA (1980) concluded that because pentanes are found in
 
gasoline, significant amounts of ethylene oxide are probably released
 
annually into the atmosphere from automobile exhaust.
 
WHO (1985) reported that the estimated air emissions due to
 
agricultural fumigation and disinfection of medical products were about
 
2% (about 53,000 tons or 48,000 kkg) of the total ethylene oxide
 
production, which was estimated at about 2.4 million tons (2.2 million
 
kkg) in the United States during 1980. The use of ethylene oxide in
 
hospitals was estimated to be less than 0.02% of the total United States
 
production, or about 500 tons (450 kkg) during 1976 (Glaser 1979).
 
5.2.2 Water
 
Ethylene oxide discharges into water also appear to be mostly
 
industry-related. According to EPA (1982a), industrial producers of
 
ethylene oxide estimated that about 800,000 pounds of this compound were
 
discharged into wastewater treatment systems each year in the United
 
States. EPA (1982a) also reported that ethylene oxide was not detected
 
in treated industrial wastewaters discharged into waterways. WHO (1985)
 
also indicated that biological treatment of wastewaters containing
 
ethylene oxide appears to be successful in the removal of this chemical
 
from reaching waterways. Contract Laboratory Program (CLP) statistical
 
data from November 1988 appear to verify this assertion. A review of
 
this data base indicated that of 5,300 water samples collected from 862
 
sites, only two sites had samples contaminated with ethylene oxide,
 
including a surface water site with a concentration of 28 µg/L and a
 
groundwater site with 21 µg/L (mean of two samples) (CLPSD 1988).
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5.2.3 Soil
 
No discharges of ethylene oxide into the soil are reported in the
 
literature. Although ethylene oxide is a potent fumigant and will kill
 
fungi, viruses, and insects, it is not approved as a soil fumigant.
 
However, since ethylene oxide is infinitely soluble in water, it is
 
likely that the soil environment is exposed to this chemical as a result
 
of the atmospheric scrubdown of rainfall and some uncontrolled
 
discharges of liquid wastes containing this chemical. The Contract
 
Laboratory Program Statistical Database (CLPSD 1988) reported that only
 
six soil samples collected from four different sites, out of 862 total
 
sites, had quantifiable amounts of ethylene oxide (mean: 22 µg/kg)
 
(CLPSD 1988).
 
5.2.4 Other Sources
 
Solid or liquid wastes containing measurable amounts of ethylene
 
oxide, as defined in Part 261 of CFR 40 (1984), can be classified as
 
hazardous with ignitable and toxic properties. However, according to
 
Bogyo et al. (1980), no specific wastes containing large amounts of
 
ethylene oxide associated with the manufacture of ethylene oxide have
 
been identified.
 
5.3 ENVIRONMENTAL FATE
 
5.3.1 Transport and Partitioning
 
The primary mode of transport of ethylene oxide is via air 
emissions into the atmosphere. At atmospheric pressure and room 
temperature, ethylene oxide exists as a gas due to its very high vapor 
pressure (1,095 mm Hg at 20°C) and low boiling point (10.4° C) (WHO 
1985). 
The reported log of the octanol/water partition coefficient (KOW)
 
for ethylene oxide is -0.30 (Hansch and Leo 1979), indicating that
 
ethylene oxide is a very polar chemical. From its chemical and physical
 
properties, it can be inferred that ethylene oxide in soil will
 
volatilize as water evaporates, leach through the soil, or be removed by
 
runoff during rainstorms. It is, therefore, unlikely that ethylene
 
oxide will accumulate in soils or sediments. No data on the
 
accumulation and/or fate of ethylene oxide in the soil environment are
 
available.
 
EPA (1984b) indicated that there are no data on the bioaccumulation
 
of ethylene oxide in animal tissue.
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Although ethylene oxide dissolves in water in any proportion, it
 
also has the tendency to escape (volatilize) due in part to its high
 
vapor pressure. Conway et al. (1983) reported that about 95% of
 
ethylene oxide mixed with water volatilizes within 4 hours (its half-life
 
is about 1 hour).
 
Ethylene oxide is used as a fumigant for some food commodities.
 
The Environmental Protection Agency (198413) reported the use of ethylene
 
oxide to fumigate cocoa, flour, dried fruits, dehydrated vegetables,
 
fish, and bone meal. However, Meister (1988) listed ethylene oxide as a
 
fumigant and sterilizing agent for only three food products: spices,
 
black walnuts and copra. Currently, EPA has set tolerances for residues
 
on these three items (see Table 7-l).
 
5.3.2 Transformation and Degradation
 
5.3.2.1 Air
 
There is limited information on the fate of ethylene oxide in the 
atmosphere. EPA (1984b) reported that the most probable path of 
atmospheric degradation of ethylene oxide is oxidation via free-radical 
formation, and estimated its half-life in air at 25°C to range from 69 
to 149 days, based on data (rate constants and the concentration of OH 
radicals) obtained by Fritz et al. (1982). 
Ethylene oxide also reacts with atmospheric oxygen in the presence 
of nitrogen dioxide and W light. Studies by Gomer and Noyes (1950) 
indicated that photocatalyzed chemical decomposition of ethylene oxide 
would result in the formation of methane, ethane, hydrogen, carbon 
dioxide, and some smaller amounts of simple aldehydes. Jaffe (1971) 
examined ethylene oxide decomposition products and postulated that 
ethylene oxide reacts with W-excited nitrogen dioxide molecules, 
eventually leading to the formation of acetaldehyde, methane, and carbon 
dioxide. According to EPA (1984b), measurements of the absolute rate 
constant, determined to be about 6 x l0-l6 cm3/mole/sec by Bogan and Hand 
(1978) for the reaction between oxygen and ethylene oxide at 27° C, 
indicate an ethylene oxide half-life of about 1,400 years, assuming an 
atmospheric oxygen concentration of 25,000 molecules/cm3. Bogan and 
Hand (1978) determined the final products of oxygen-W catalyzed 
ethylene oxide oxidation to be hydrogen, water, carbon monoxide, carbon 
dioxide, and formaldehyde. Joshi et al. (1982) determined ethylene 
oxide to have a low reactivity with atmospheric nitrogen dioxide under 
W radiation and at 25° C. Using ethylene oxide:nitrogen dioxide ratios 
similar to those found in urban and rural air, these researchers 
reported the ethylene oxide half-life to be more than 53 hours. 
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In summary, the few available studies on the photodecomposition of
 
ethylene oxide in the atmosphere suggest that it undergoes measurable
 
rates of degradation into simpler products. However, laboratory
 
estimates of the half-life of ethylene oxide in the atmosphere vary
 
widely.
 
5.3.2.2 Water
 
Ethylene oxide hydrolyzes in water to form glycols (Long and 
Pritchard 1956). Bogyo et al. (1980) reported the hydrolysis rate 
constant (acid catalyzed) to be about 19.9 x l0-3 L/mol-sec at 30° C. 
According to the same report, all epoxides, including ethylene oxide, 
can react with anions such as chloride and bromide in aqueous solutions, 
forming halogenated alcohols. Conway et al. (1983) determined the 
half-life of ethylene oxide to range from 12 to 14 days in sterile, 
deionized and natural river water. They also reported that increased 
water salinity (up to 3% sodium chloride) decreased the half-life of 
ethylene oxide to 9 days (Conway et al. 1983), and produced ethanediol 
and chloroethanol. 
According to Anbar and Neta (1967), the degradation of ethylene
 
oxide in water via hydroxyl radicals is very slow, with a computed half-life
 
of about 50 years.
 
Conway et al. (1983) reported that the half-life measurements for
 
ethylene oxide in sterile and natural river water were not appreciably
 
different. This may be because hydrolytic degradation of ethylene oxide
 
is more rapid than biodegradation of this compound in aqueous media.
 
5.3.2.3 Soil
 
No studies on the degradation of ethylene oxide in the soil
 
environment have been located. However, it is likely that ethylene
 
oxide would be found in both the water and vapor phases of the soil
 
environment due to its high vapor pressure and very low octanol/water
 
partition coefficient. Thus, ethylene oxide in the soil is likely to
 
undergo at least some degradation via the same types of mechanisms as
 
those that predominate in aquatic environments.
 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
 
5.4.1 Air
 
There is very little information on ethylene oxide levels in air,
 
but the data available indicate that ethylene oxide does not seem to be
 
a contaminant in ambient air. Hunt et al. (1986) conducted an air
 
quality survey in Texas during 1985 and 1986. Quarterly state and local
 
air quality measurements indicated that ethylene oxide was not detected
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at concentrations above the detection limit of 0.194 ng/m3. These
 
authors also reported that ethylene oxide was not detected in a
 
comprehensive air quality survey in the state of California.
 
5.4.2 Water
 
There are very limited data on the presence or absence of ethylene
 
oxide in water (drinking water supplies, groundwater, etc.) on a
 
national scale. EPA (1984b) reported a survey showing ethylene oxide at
 
a concentration of 2 mg/L in the effluent of a chemical plant in
 
Bandenburg, Kentucky.
 
5.4.3 Soil
 
No data are available on the presence or absence of any significant
 
levels of ethylene oxide in soil. However, DeBont and Albers (1976)
 
reported that ethylene oxide is produced by the metabolism of ethylene
 
by an ethylene-oxidizing bacterium. Also, ethylene is a relatively
 
common volatile hydrocarbon in wet soil, where it can be produced by
 
several species of fungi, bacteria, and actinomycetes (Alexander 1977).
 
Therefore, small but constant levels of ethylene oxide may be present in
 
soils under wet conditions. No data are available on ethylene oxide in
 
soils resulting from uncontrolled releases of ethylene oxide liquid
 
waste or from atmospheric depositions of any kind.
 
5.4.4 Other Media
 
Ethylene oxide may be found in tobacco and some food as a result of 
its use as a fumigant and a sterilizing agent. The Farm Chemicals 
Handbook (Meister 1988) lists ethylene oxide for use only as a fumigant 
on three food products: spices, black walnuts and copra. However, 
ethylene oxide may have been used (and may still be used) as a fumigant 
for tobacco and some cosmetics. Measurable amounts of ethylene oxide 
were detected in both fumigated and unfumigated tobacco and its smoke; 
the ethylene oxide concentration in smoke from unfumigated tobacco was 
1 µg/g (Bogyo et al. 1980). 
Residual ethylene oxide may be found in foods temporarily,
 
following fumigation. Scudamore and Heuser (1971) reported that
 
ethylene oxide may react with water and inorganic halides (chloride and
 
bromide) from foods and produce glycols and halohydrins. The same
 
researchers concluded that the persistence or disappearance of ethylene
 
oxide and its byproducts in fumigated commodities depends on the grain
 
size, type of foods, aeration procedures, temperature, and storage and
 
cooking conditions. According to Scudamore and Heuser (1971), most
 
experimentally fumigated commodities had levels of ethylene oxide below
 
1 ppm after 14 days in normal storage conditions. No residues of
 
ethylene oxide were found in commercially fumigated flour or tobacco.
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Rajendran and Muthu (1981) reported that concentrations of ethylene
 
oxide in 24-hour aerated foods (wheat, rice, spices, dates and peas)
 
(following a 24-hour fumigation period) ranged from 0 to 3.5 ppm. IARC
 
(1976) indicated that food fumigated with ethylene oxide generally had
 
negligible levels of ethylene oxide within a few hours after fumigation,
 
due primarily to loss by volatilization. However, in spices, ethylene
 
oxide levels ranging from 53 to 116 mg/kg (ppm) and about 25 mg/kg (ppm)
 
at 2 days and 26 days after fumigation, respectively have been reported
 
(WHO 1985).
 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
 
The general population's exposure to ethylene oxide may occur via
 
inhalation and food ingestion. There is no information to indicate that
 
ethylene oxide is a common contaminant of drinking water supplies.
 
Since ethylene oxide is used as a sterilant and fumigant, the
 
potential locations of contaminated air include hospitals (ethylene
 
oxide is commonly used to sterilize medical equipment), libraries,
 
museums, and laboratories. Sources include vapors from certain foods,
 
clothing, cosmetics, and beekeeping equipment (NIOSH 1981).
 
Sources of exposure of the general population to ethylene oxide may
 
be the by-products of gasoline combustion and cigarette smoke. There is
 
also some evidence that some foods such as flour and spices retain
 
measurable ethylene oxide and by-products several months after
 
fumigation. Ethylene oxide exposure levels of the general population
 
via air, water, or foods have not been found in the available literature
 
or from national surveys and have not been estimated.
 
Occupational groups exposed to ethylene oxide include workers in
 
ethylene oxide manufacturing or processing plants, sterilization
 
technicians, workers involved in the fumigation of foods, clothing, and
 
cosmetics, and indoor fumigators. OSHA (1988b) estimates that 67,728
 
workers were exposed to ethylene oxide in 1988. OSHA and ACGIH have
 
established an 8-hour workshift exposure limit of 1 ppm (ACGIH 1986;
 
OSHA 1988b). However, NIOSH (1985b) recommends the exposure level to be
 
0.1 ppm or less over 8 hours, not to exceed 5 ppm for more than
 
10 minutes. The odor threshold of ethylene oxide in air is 430 ppm
 
(Amoore and Hautala 1983), which is well above the OSHA PEL (1 ppm).
 
Thus, worker exposure to ethylene oxide can be determined only through
 
routine air monitoring.
 
Hospital workers and patients may be exposed to residual levels of
 
ethylene oxide from the sterilization of hospital equipment. Some
 
sterilized plastics may retain concentrations of ethylene oxide ranging
 
from 3 to 443 mg/kg (ppm) even after seven days of aeration (WHO 1985).
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Other medical equipment such as adhesive dressings and cotton wool pads
 
may also retain ethylene oxide at 2 mg/kg (ppm) or less for 7 to 8 days
 
after sterilization (Dauvois et al. 1982).
 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
 
Technicians involved in routine disinfection of medical equipment
 
in hospitals may be exposed to relatively high levels of ethylene oxide.
 
Studies of worker exposures in five hospital sterilization rooms in the
 
United States indicate that the time-averaged exposures range from less
 
than 0.1 to 4.3 ppm, with peaks as high as 795 ppm (Hansen et al. 1984).
 
Brugnone et al. (1985) have reported alveolar concentrations of ethylene
 
oxide to be about 75% of the environmental concentrations of ethylene
 
oxide in a hospital sterilizing unit (0.1 to 7.8 ppm); the OSHA timeweighted­
average limit is 1 ppm and the 15-minute excursion limit is
 
5 mm. Occupational exposure levels estimated by OSHA (1988b) range
 
from 0.08 to 3.97 ppm (8-hour TWA) and 0.24 to 32.2 ppm (15-minute) (see
 
Table 7-l).
 
According to Flores (1983), workers in chemical manufacturing
 
plants in the United States may also be exposed to high levels of
 
ethylene oxide in air; typical average daily exposure levels ranging
 
from 0.2 to 2.2 ppm were measured during 1979. Some isolated incidents
 
of very high (peak) worker exposures have also occurred as a result of
 
plant breakdowns (Flores 1983; Thiess et al. 1981). It is expected that
 
occupational exposures will be reduced because of recent OSHA
 
regulations (OSHA 1988b).
 
5.7 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of
 
the Public Health Service) to assess whether adequate information on the
 
health effects of ethylene oxide is available. Where adequate
 
information is not available, ATSDR, in conjunction with the NTP, is
 
required to assure the initiation of a program of research designed to
 
determine the health effects (and techniques for developing methods to
 
determine such health effects) of ethylene oxide.
 
The following categories of possible data needs have been
 
identified by a joint team of scientists from ATSDR, NTP, and EPA. They
 
are defined as substance-specific informational needs that, if met would
 
reduce or eliminate the uncertainties of human health assessment. In
 
the future, the identified data needs will be evaluated and prioritized,
 
and a substance-specific research agenda will be proposed.
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5.7.1 Identification of Data Needs
 
Physical and Chemical Properties. Ethylene oxide is commonly used
 
in the synthesis of many other products, and its basic physical and
 
chemical properties are well known and documented (see Chapter 3).
 
However, data on the properties related to its fate in the environment
 
are less reliable or are totally lacking. For example, there are no
 
recent studies that verify the degradation rates of ethylene oxide in
 
air. Also, there is only one study, Conway et al. (1983), that provides
 
data on the rates of degradation and on water to air transfer of
 
ethylene oxide during the 1980s. There are no data on the fate and
 
transport of ethylene oxide in the soil environment. Since ethylene
 
oxide is a gas and a polar solute in water, these types of data are
 
particularly important for media with water-saturated or near saturated
 
conditions, such as landfills. Data on the rates of microbial
 
degradation and toxicity of ethylene oxide in soils are needed.
 
Production, Use, Release, and Disposal. Available production, use,
 
release, and disposal data indicate that most ethylene oxide
 
manufactured in the United states is consumed in the synthesis of other
 
chemicals. However, current quantitative data on the amounts of
 
ethylene oxide released to the environment during ethylene oxide
 
production and use are sparse. This information would be helpful in
 
evaluating the effect of industrial practices on environmental levels of
 
ethylene oxide.
 
According to the Emergency Planning and Community Right to Know Act
 
of 1986 (EPCRTKA), (§313), (Pub. L. 99-499, Title III, §313), industries
 
are required to submit release information to the EPA. The Toxics
 
Release Inventory (TRI), which contains release information for 1987,
 
became available in May of 1989. This database will be updated yearly
 
and should provide a more reliable estimate of industrial production and
 
emission.
 
Environmental Fate. Data on the fate of ethylene oxide in the
 
atmosphere are limited. The half-life estimates of this chemical should
 
be refined and include measurements in the stratosphere. Since ethylene
 
oxide has been shown to slowly react with oxygen, stratospheric
 
measurements should also include data on the potential impact of
 
ethylene oxide on the ozone layer. Data on the fate of ethylene oxide
 
in the water environment are available but are very limited. More
 
information is needed on the rates of transport of ethylene oxide
 
between water and air. Also, more data on the rates of biodegradation
 
of ethylene oxide in natural environments such as lakes, rivers,
 
groundwater, and soil are needed. Data on the fate of ethylene oxide in
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the soil environment would be useful. Because all of the ethylene oxide
 
that does not degrade in the atmosphere eventually returns to the soil
 
and water, data on transport and degradation of ethylene oxide would be
 
helpful in determining its potential contamination of water supplies.
 
Bioavailability from Environmental Media. Ethylene oxide has been
 
shown to be absorbed following inhalation of contaminated air. However,
 
there are no data on absorption after oral or dermal administration of
 
this compound. No information was located on the bioavailability of
 
ethylene oxide from contaminated water, soil, or plant material. These
 
data would be useful in determining potential exposure levels for
 
organisms (humans, animals, and plants) that may have contact with
 
ethylene oxide in these media.
 
Food Chain Bioaccumulation. WHO (1985) has concluded that ethylene
 
oxide will not bioaccumulate in animals since it is readily metabolized
 
via hydrolysis and glutathione conjugation and excretion. This
 
conclusion was based on the review of several studies in both humans and
 
animals (terrestrial and marine species). No data are available in the
 
literature that indicate that ethylene oxide bioaccumulates in plants.
 
Research on the possible mechanisms of plant uptake, absorption and
 
assimilation of ethylene oxide would be useful since it may be a common
 
and natural constituent in the soil environment, as discussed in
 
Section 5.4.3, and because it is also an atmospheric pollutant.
 
Exposure Levels in Environmental Media. Neither environmental
 
monitoring nor background data are available for ethylene oxide in soil,
 
air, or water. Ambient concentrations of ethylene oxide are not known
 
in high density urban and industrial areas which have potentially large
 
sources of ethylene oxide such as car exhaust or point sources
 
(industrial). These data would be helpful in determining the ambient
 
concentrations of ethylene oxide so that exposure estimates can be made
 
for the general population.
 
Exposure Levels in Humans. Available data indicate that some work
 
environments provide continuous exposure to ethylene oxide at levels
 
that may exceed OSHA regulations. Data on other industrial workers such
 
as building and agricultural fumigators and construction workers would
 
be useful.
 
Estimates of the exposure levels of the general population would
 
also be helpful.
 
Exposure Registries. No exposure registries for ethylene oxide
 
were located. This compound is not currently one of the compounds for
 
which a subregistry has been established in the National Exposure
 
Registry. The compound will be considered in the future when chemical
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selection is made for subregistries to be established. The information
 
that is amassed in the National Exposure Registry facilitates the
 
epidemiological research needed to assess adverse health outcomes that
 
may be related to the exposure to this compound.
 
5.7.2 On-going Studies
 
No on-going studies related to the potential for human exposure to
 
ethylene oxide were located in the available literature.
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The purpose of this chapter is to describe the analytical methods
 
that are available for detecting and/or measuring and monitoring
 
ethylene oxide in environmental media and in biological samples. The
 
intent is not to provide an exhaustive list of analytical methods that
 
could be used to detect and quantify ethylene oxide. Rather, the
 
intention is to identify well-established methods that are used as the
 
standard methods of analysis. Many of the analytical methods used to
 
detect ethylene oxide in environmental samples are the methods approved
 
by federal agencies such as EPA and the National Institute for
 
Occupational Safety and Health (NIOSH). Other methods presented in this
 
chapter are those that are approved by a trade association such as the
 
Association of Official Analytical Chemists (AOAC) and by the American
 
Public Health Association (APHA). Additionally, analytical methods are
 
included that refine previously used methods to obtain lower detection
 
limits, and/or to improve accuracy and precision.
 
6.1 BIOLOGICAL MATERIALS
 
Ethylene oxide is relatively reactive in biological systems and
 
undergoes chemisorption to biological materials to form addition
 
products with compounds that contain hydroxyl, phenolic, carbonyl,
 
amino, or sulfhydryl groups. Therefore, it is usually necessary in
 
biological samples to determine these addition products. Examples of
 
such products that are determined to measure in vivo exposure to
 
ethylene oxide are N-(2-hydroxyethyl)histidine and N­
(2-hydroxyethyl)valine (Bailey et al. 1987; Farmer et al. 1986).
 
Methods have been published for the determination of ethylene oxide in
 
blood and alveolar air (Brugnone et al. 1986).
 
As with other materials in biological samples, samples containing
 
ethylene oxide, its reaction products, and its metabolites must undergo
 
some form of sample cleanup prior to analysis. Cleanup is a separation
 
procedure that ideally isolates the analyte in a mixture, concentrates
 
it, and eliminates most of the sample matrix. The chemical and
 
biochemical reactivity of ethylene oxide complicates the cleanup of the
 
biological samples in which it is contained.
 
Methods for the determination of ethylene oxide and its reaction
 
products in biological samples are summarized in Table 6-l.
 
6.2 ENVIRONMENTAL SAMPLES
 
Ethylene oxide in environmental samples is most commonly determined
 
after derivatization to stable, volatile halogenated species,
 
particularly 2-bromoethanol (Cummins et al. 1987), followed by gas
 
chromatography with an electron capture detector (GC/ECD) for
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halogenated derivatives, or by gas chromatography/mass spectrometry
 
(GC/MS) (Farmer et al. 1986). Infrared spectrometry may also be used
 
(APHA 1985). A sensitive method for ethylene oxide determination has
 
been published in which the brominated compound is formed in a standard
 
solution of propylene oxide and the chromatographic peak ratios for the
 
brominated ethylene oxide and propylene oxide derivatives are compared
 
(Kikuchi et al. 1988).
 
The most straightforward means of determining ethylene oxide in air
 
is direct analysis of air samples without analyte collection. This has
 
been done with a portable gas chromatograph using clean air as a carrier
 
gas and a photoionization detector (PID) for detection (Bond and Dumas
 
1982; Collins and Barker 1983). Ethylene oxide can be concentrated from
 
air samples with a solid sorbent, desorbed with carbon disulfide, and
 
measured by gas chromatography (NIOSH 1977). A major problem with this
 
approach is the reaction of ethylene oxide with moisture or with
 
halides, resulting in loss of the analyte. However, this reaction
 
tendency can be used to advantage by derivatization of ethylene oxide to
 
2-bromoethanol on a collection column treated with hydrobromic acid,
 
followed by elution of the product with benzene/carbon disulfide and
 
measurement by GC/ECD. In the analysis of ethylene oxide in air by
 
direct GC/ECD determination of 2-bromoethanol formed by reaction of
 
ethylene oxide with HBr on HBr-coated charcoal, reproducibility problems
 
have been encountered as a consequence of interference by unreacted HBr
 
(Cummins et al. 1987). This interference has been overcome by forming a
 
derivative of 2-bromoethanol by reaction with heptafluorobutyrylimidazole
 
and measuring the product with GC/ECD (Cummins et al. 1987).
 
A method for the determination of ethylene oxide in water and in
 
soil by partition infrared spectrophotometry has been reported (APHA
 
1985; Environment Canada 1985).
 
Methods for the determination of ethylene oxide in environmental
 
samples are summarized in Table 6-2.
 
6.3 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of
 
the Public Health Service) to assess whether adequate information on the
 
health effects of ethylene oxide is available. Where adequate
 
information is not available, ATSDR, in conjunction with the NTP, is
 
required to assure the initiation of a program of research designed to
 
determine the health effects (and techniques for developing methods to
 
determine such health effects) of ethylene oxide.
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The following categories of possible data needs have been
 
identified by a joint team of scientists from ATSDR, NTP, and EPA. They
 
are defined as substance-specific informational needs that, if met would
 
reduce or eliminate the uncertainties of human health assessment. In
 
the future, the identified data needs will be evaluated and prioritized,
 
and a substance-specific research agenda will be proposed.
 
6.3.1 Identification of Data Needs
 
Methods for Determining Biomarkers of Exposure and Effect.
 
Ethylene oxide is rapidly metabolized in biological systems and tends to
 
form addition products such as N-(2-hydroxyethyl)histidine and N­
(2-hydroxyethyl)valine. Although existing methodology is adequate to
 
provide qualitative evidence of exposure, it would be useful to have the
 
means to determine corresponding levels of exposure to ethylene oxide
 
from the levels of these substances in biological media.
 
There are currently no available methods that can be used to
 
associate the levels of ethylene oxide in biological media with the
 
onset of adverse health effects. Further information in this area would
 
be useful. It is not known if existing methods are sensitive enough to
 
measure background levels of these compounds in the blood, urine or
 
other biological media of the general population.
 
Supercritical fluid extraction coupled with supercritical fluid
 
chromatography and immunoassay analysis are two areas of intense current
 
activity from which substantial advances in the determination of
 
ethylene oxide metabolites in biological samples can be anticipated.
 
The two techniques are complementary in that supercritical fluid
 
extraction is especially promising for the removal of analytes from
 
sample materials and immunoassay analysis is very analyte selective and
 
sensitive (Vanderlaan 1988). This combination has been described for
 
the determination of sulfonylurea herbicides and their metabolites in
 
complex media including soil, plant materials, and a cell culture medium
 
(McNally and Wheeler 1988). This technique should be applicable to many
 
other toxicologically and environmentally significant analytes including
 
ethylene oxide metabolites.
 
Methods for Determining Parent Compounds and Degradation Products
 
in Environmental Media. Methods are available for the determination of
 
ethylene oxide in a clean, dry, gas-phase matrix. However, because of
 
ethylene oxide's reactivity, its determination in air, water and soil
 
matrices is difficult. The development of methods for analysis of
 
ethylene oxide that have improved sensitivity and selectivity would be
 
useful.
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There is an ongoing effort to develop a "Master Analytical Scheme" 
for organic compounds in water (Michael et al. 1988). The overall goal 
is the development of technology capable of detecting and measuring 
organic compounds present at levels of 0.1 µg/L in drinking water, 
1 µg/L in surface water, and 10 µg/L in effluent waters. In addition to 
volatile compounds (bp < 150° C), analytes are to include numerous 
semivolatile compounds and some compounds that are sparingly soluble in 
water. 
Determination of the degradation products of ethylene oxide in
 
environmental media is difficult, not because of analytical problems,
 
but because the fundamental environmental chemistry of these compounds
 
in water, soil, air, and biological systems is not known.
 
The development of analytical methods to measure ethylene oxide in
 
situ in water and other environmental media could contribute to
 
environmental studies of this compound.
 
6.3.2 On-going Studies
 
Studies designed to improve methods for the determination of
 
environmental contaminants may provide refinements and improvements in
 
the determination of ethylene oxide. The current high level of activity
 
in supercritical fluid extraction of solid and semisolid samples should
 
yield improved recoveries and sensitivities for the determination of
 
ethylene oxide and its environmental degradation products in solid
 
wastes, and these compounds should be amenable to supercritical fluid
 
chromatographic analysis. Immunoassay analysis (Vanderlaan 1988) is an
 
area of intense current activity from which substantial advances in the
 
determination of ethylene oxide in environmental samples can be
 
anticipated.
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7. REGULATIONS AND ADVISORIES
 
Because of its potential to cause adverse health effects in exposed
 
persons, a number of regulations and advisories have been established
 
for ethylene oxide by various international, national, and state
 
agencies. These regulations and advisories are summarized in Table 7-l.
 



____________ 
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9. GLOSSARY
 
Acute Exposure -- Exposure to a chemical for a duration of 14 days or
 
less, as specified in the Toxicological Profiles.
 
Adsorption Coefficient (K
oc
) -- The ratio of the amount of a chemical
 
adsorbed per unit weight of organic carbon in the soil or sediment to
 
the concentration of the chemical in solution at equilibrium.
 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment
 
or soil (i.e., the solid phase) divided by the amount of chemical in the
 
solution phase, which is in equilibrium with the solid phase, at a fixed
 
solid/solution ratio. It is generally expressed in micrograms of
 
chemical sorbed per gram of soil or sediment.
 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
 
chemical in aquatic organisms at a specific time or during a discrete
 
time period of exposure divided by the concentration in the surrounding
 
water at the same time or during the same time period.
 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study or
 
group of studies which produces significant increases in incidence of
 
cancer (or tumors) between the exposed population and its appropriate
 
control.
 
Carcinogen -- A chemical capable of inducing cancer.
 
Ceiling value (CL) -- A concentration of a substance that should not be
 
exceeded, even instantaneously.
 
Chronic Exposure -- Exposure to a chemical for 365 days or more, as
 
specified in the Toxicological Profiles.
 
Developmental Toxicity -- The occurrence of adverse effects on the
 
developing organism that may result from exposure to a chemical prior to
 
conception (either parent), during prenatal development, or postnatally
 
to the time of sexual maturation. Adverse developmental effects may be
 
detected at any point in the life span of the organism.
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Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as
 
a result of prenatal exposure to a chemical; the distinguishing feature
 
between the two terms is the stage of development during which the
 
insult occurred. The terms, as used here, include malformations and
 
variations, altered growth, and in utero death.
 
EPA Health Advisory -- An estimate of acceptable drinking water levels
 
for a chemical substance based on health effects information. A health
 
advisory is not a legally enforceable federal standard, but serves as
 
technical guidance to assist federal, state, and local officials.
 
Immediately Dangerous to Life or Health (IDLH) -- The maximum
 
environmental concentration of a contaminant from which one could escape
 
within 30 min without any escape-impairing symptoms or irreversible
 
health effects.
 
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364
 
days, as specified in the Toxicological Profiles.
 
Immunologic Toxicity -- The occurrence of adverse effects on the immune
 
system that may result from exposure to environmental agents such as
 
chemicals.
 
In Vitro -- Isolated from the living organism and artificially
 
maintained, as in a test tube.
 
In Vivo -- Occurring within the living organism.
 
Lethal Concentration(LO) (LCLO) -- The lowest concentration of a chemical
 
in air which has been reported to have caused death in humans or
 
animals.
 
Lethal Concentration(50) (LC50) -- A calculated concentration of a
 
chemical in air to which exposure for a specific length of time is
 
expected to cause death in 50% of a defined experimental animal
 
population.
 
Lethal Dose (LO) (LDLO) -- The lowest dose of a chemical introduced by a
 
route other than inhalation that is expected to have caused death in
 
humans or animals.
 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been
 
calculated to cause death in 50% of a defined experimental animal
 
population.
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Lethal Time(50) (LT50) -- A calculated period of time within which a
 
specific concentration of a chemical is expected to cause death in 50%
 
of a defined experimental animal population.
 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of
 
chemical in a study or group of studies which produces statistically or
 
biologically significant increases in frequency or severity of adverse
 
effects between the exposed population and its appropriate control.
 
Malformations -- Permanent structural changes that may adversely affect
 
survival, development, or function.
 
Minimal Risk Level (MRL) -- An estimate of daily human exposure to a
 
chemical that is likely to be without an appreciable risk of deleterious
 
effects (noncancerous) over a specified duration of exposure.
 
Mutagen -- A substance that causes mutations. A mutation is a change in
 
the genetic material in a body cell. Mutations can lead to birth
 
defects, miscarriages, or cancer.
 
Neurotoxicity -- The occurrence of adverse effects on the nervous system
 
following exposure to a chemical.
 
No-Observed-Adverse-Effect Level (NOAEL) -- That dose of chemical at
 
which there are no statistically or biologically significant increases
 
in frequency or severity of adverse effects seen between the exposed
 
population and its appropriate control. Effects may be produced at this
 
dose, but they are not considered to be adverse.
 
Octanol-Water Partition Coefficient (K
ow
) -- The equilibrium ratio of
 
the concentrations of a chemical in n-octanol and water, in dilute
 
solution.
 
Permissible Exposure Limit (PEL) -- An allowable exposure level in
 
workplace air averaged over an 8-hour shift.
 
q1* -- The upper-bound estimate of the low-dose slope of the dose response
 
curve as determined by the multistage procedure. The q1* can
 
be used to calculate an estimate of carcinogenic potency, the
 
incremental excess cancer risk per unit of exposure (usually µg/L for
 
water, mg/kg/day for food, and µg/m3 for air).
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Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps
 
an order of magnitude) of the daily exposure of the human population to
 
a potential hazard that is likely to be without risk of deleterious
 
effects during a lifetime. The RfD is operationally derived from the
 
NOAEL (from animal and human studies) by a consistent application of
 
uncertainty factors that reflect various types of data used to estimate
 
RfDs and an additional modifying factor, which is based on a
 
professional judgment of the entire database on the chemical. The RfDs
 
are not applicable to nonthreshold effects such as cancer.
 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that
 
is considered reportable under CERCLA. Reportable quantities are: (1) 1
 
lb or greater or (2) for selected substances, an amount established by
 
regulation either under CERCLA or under Sect. 311 of the Clean Water
 
Act. Quantities are measured over a 24-hour period.
 
Reproductive Toxicity -- The occurrence of adverse effects on the
 
reproductive system that may result from exposure to a chemical. The
 
toxicity may be directed to the reproductive organs and/or the related
 
endocrine system. The manifestation of such toxicity may be noted as
 
alterations in sexual behavior, fertility, pregnancy outcomes, or
 
modifications in other functions that are dependent on the integrity of
 
this system.
 
Short-Term Exposure Limit (STEL) -- The maximum concentration to which
 
workers can be exposed for up to 15 min continually. No more than four
 
excursions are allowed per day, and there must be at least 60 min
 
between exposure periods. The daily TLV-TWA may not be exceeded.
 
Target Organ Toxicity -- This term covers a broad range of adverse
 
effects on target organs or physiological systems (e.g., renal,
 
cardiovascular) extending from those arising through a single limited
 
exposure to those assumed over a lifetime of exposure to a chemical.
 
Teratogen -- A chemical that causes structural defects that affect the
 
development of an organism.
 
Threshold Limit Value (TLV) -- A concentration of a substance to which
 
most workers can be exposed without adverse effect. The TLV may be
 
expressed as a TWA, as a STEL, or as a CL.
 
Time-weighted Average (TWA) -- An allowable exposure concentration
 
averaged over a normal 8-hour workday or 40-hour workweek.
 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a
 
route other than inhalation, which is expected to cause a specific toxic
 
effect in 50% of a defined experimental animal population.
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Uncertainty Factor (UF) -- A factor used in operationally deriving the
 
RfD from experimental data. UFs are intended to account for (1) the
 
variation in sensitivity among the members of the human population, (2)
 
the uncertainty in extrapolating animal data to the case of humans, (3)
 
the uncertainty in extrapolating from data obtained in a study that is
 
of less than lifetime exposure, and (4) the uncertainty in using LOAEL
 
data rather than NOAEL data. Usually each of these factors is set equal
 
to 10.
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APPENDIX
 
PEER REVIEW
 
A peer review panel was assembled for ethylene oxide. The panel
 
consisted of the following members: DK. Martin Alexander, Professor,
 
Department of Agronomy, Cornell University; Dr. Richard Thomas,
 
Consulting Toxicologist, Thomas and Thomas Technologies, Inc.; and
 
Dr. Mohammed Mustafa, School of Public Health, University of California.
 
These experts collectively have knowledge of ethylene oxide's physical
 
and chemical properties, toxicokinetics, key health end points,
 
mechanisms of action, human and animal exposure, and quantification of
 
risk to humans. All reviewers were selected in conformity with the
 
conditions for peer review specified in the Superfund Amendments and
 
Reauthorization Act of 1986, Section 110.
 
A joint panel of scientists from ATSDR and EPA has reviewed the
 
peer reviewers' comments and determined which comments will be included
 
in the profile. A listing of the peer reviewers' comments not
 
incorporated in the profile, with a brief explanation of the rationale
 
for their exclusion, exists as part of the administrative record for
 
this compound. A list of databases reviewed and a list of unpublished
 
documents cited are also included in the administrative record.
 
The citation of the peer review panel should not be understood to
 
imply their approval of the profile's final content. The responsibility
 
for the content of this profile lies with the Agency for Toxic
 
Substances and Disease Registry.
 

